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Die Alzheimer-Demenz (AD), lateinisch Morbus Alzheimer, ist eine neurodegenerative 
Erkrankung, die durch die fortschreitende Abnahme kognitiver Funktionen 
gekennzeichnet ist und mit Verhaltensstörungen und neuropsychologischen 
Symptomen assoziiert. Bis heute ist die Behandlung von AD nur symptomatisch.  Trotz 
der bisherigen Forschungsanstrengungen ist kein kausales Medikament zugelassen, 
welches den Krankheitsverlauf aufgehalten oder rückgängig machen kann.  
Die Hauptmerkmale der AD sind die Entstehung von amyloiden Plaques und das 
Auftreten von neurofibrilliären Bündeln. Neurofibrilliäre Bündel bestehen hauptsächlich 
aus aggregierten Tau-Proteinen. Tau-Protein-Aggregation führt zu einem Verlust der 
Tau-Funktion (etwa der Stabilisierung der Mikrotubuli) sowie zu Neurotoxizität und 
Zelldegeneration. Die Bildung amyloider Tau-Aggregate wird innerhalb von Tau durch 
zwei aus sechs Aminosäuren bestehenden Fragmente angetrieben: i) VQIINK 
(PHF6*), zu Beginn von Repeat 2 gelegen, und ii) VQIVYK (PHF6), zu Beginn von 
Repeat 3 gelegen. Es wurde kürzlich beschrieben, dass das PHF6*-Segment die 
pathologische Tau-Aggregation stärker antreibt als das PHF6-Fragment.  
Peptide, die die Tau-Aggregation inhibieren, sind mögliche Kandidaten für zukünftige 
Therapien bei Alzheimer. Zur Selektion affiner Peptide für spezielle Bindepartner ist 
die molekularbiologische Methode des Phagendisplays eine einfache und schnelle 
Möglichkeit.  
Ziel dieser Arbeit war es, D-enantiomere Peptide zu entwickeln, die die pathologische  
Aggregation des Tau-Proteins hemmen können. D-Peptide können L-Peptiden für 
Anwendungen in vivo überlegen sein, da sie proteaseresistent sind und in der Regel 
das Immunsystem nicht aktivieren.  
Ein weiteres Ziel dieser Arbeit war es herauszufinden, welches der beiden Tau 
Fragmente, PHF6 oder PHF6*, das bedeutsamere therapeutische Target für die 
Entwicklung von Tau-Aggregations-inhibierenden Peptiden ist.  
Mittels Phagendisplay und Spiegelbild-Phagendisplay konnten D-Peptide entwickelt 
werden, die die Formation von Tau-Fibrillen inhibierten. Zwei Selektionen wurden 




durchgeführt; die zweite Selektion wurde gegen D-Enantiomere PHF6*-Fibrillen mittels 
Spiegelbild-Phagendisplay durchgeführt. PHF6*-fibrillen wurden in der zweiten 
Selektion adressiert, da eine aktuelle Studie zeigte, dass die PHF6*-Sequenz die 
Aggregation des Tau-Proteins stärker antreibt als die PHF6-Sequenz.  
 
Das besonders vielversprechende Peptid MMD3 wurde sowohl in der Selektion gegen 
Tau-Monomer als auch in der Selektion gegen D-Enantiomere PHF6*-Fibrillen 
identifiziert. Es konnte per Thioflavin-Assay bestätigt werden, dass MMD3 und seine 
retro-inverse Version MMD3rev sowohl die Aggregation von PHF6* als auch die 
Fibrillenbildung des Volllänge-Tau-Proteins inhibierten.   
In einem ersten Ansatz zur Untersuchung, welches der beiden Hexapeptide innerhalb 
von Tau, PHF6 oder PHF6*, das effektivere Ziel zur Aggregations-Inhibition ist, wurde 
die inhibitorische Wirkung von MMD3 und MMD3rev (gerichtet gegen PHF6*) mit den 
bereits beschriebenen Peptiden, die gegen PHF6 bzw. PHF6* gerichtet sind, 
verglichen. Dieses erste vorläufige Ergebnis zeigte, dass gegen PHF6 bzw. gegen 
PHF6*-gerichtete Peptide ähnlich wirksam in ihren aggregationsinhibierenden 
Eigenschaften sind. Allerdings steht hier eine weitere Charakterisierung mit 
verschiedenen biochemischen und biophysikalischen Methoden noch aus.  
Die in dieser Arbeit identifizierten D-Peptide MMD3 und MMD3rev sind 
vielversprechende Kandidaten für einen neuen medikamentösen Ansatz der 
Behandlung der Alzheimer-Demenz und werden aktuell bei einem 
Kooperationspartner vom Deutschen Zentrum für Neurodegenerative Erkrankungen 
(DZNE) weiter charakterisiert.  














Morbus Alzheimer (AD) is a neurodegenerative disease, characterized by steady loss 
of cognitive functions, behavioral changes and neuropsychological symptoms. Today, 
AD can be treated only symptomatically. There is no drug available, which stops or 
reverses the pathological changes in AD. Alzheimer's disease is characterized by two 
pathological hallmarks, amyloid plaques and neurofibrillary tangles (NFTs). NFTs are 
composed of aggregated tau protein. The accumulation of tau into NFTs reduces 
normal tau function and causes neuronal dysfunction. The formation of tau aggregates 
is triggered by two hexapeptide sequences within tau: VQIINK (PHF6*), which is 
located at the beginning of the second repeat (R2) and VQIVYK (PHF6), which is 
located at the beginning of the third repeat (R3). PHF6* segment has recently been 
described as a more potent driver of tau aggregation than PHF6.  
Peptides that inhibit the pathological aggregation of tau are potentially useful 
candidates for future therapies in AD. The use of the molecular biology screening 
technique, phage display, allows fast and simple selection of peptides that bind to a 
desired target protein.  
The aim of this study was to develop specific D-enantiomeric peptides that inhibit the 
pathological aggregation of tau. D-enantiomeric peptides were chosen as they are 
protease stable and considerably less immunogenic than L-peptides.  
Another objective of this project was to investigate which of the both sequences within 
tau, PHF6 or PHF6*, is the more effective target for the development of tau aggregation 
inhibiting peptides.  
Employing phage display and mirror image phage display, we selected specific 
peptides to inhibit tau fibril formation. Two selections were performed; the first selection 
was conducted using monomers of L-enantiomeric full-length tau as a target for phage 
display. In addition, we performed a second selection using fibrils of the D-enantiomeric 
hexapeptide VQIINK (PHF6*) as a target for mirror image phage display. PHF6* 
segment was targeted in our second selection since PHF6* was recently reported as 




The most interesting obtained peptide, designated MMD3, was found both in the 
selection against tau monomer and in the selection against D-PHF6* fibrils. MMD3 and 
its retro-inverso form, designated MMD3rev, clearly inhibited PHF6* aggregation as 
well as full-length tau aggregation in Thioflavin T (THT) assays.  
In addition, we performed preliminary experiments to investigate which of the both 
sequences, PHF6 or PHF6*, is the more effective target for inhibitors of tau fibril 
formation. We compared the tau aggregation inhibiting effects of MMD3 and MMD3rev 
with other peptides, which were previously described in the literature and target either 
PHF6 or PHF6*, respectively. From our early preliminary data, it seems likely that 
PHF6 and PHF6* aggregation inhibitors are comparably effective in inhibiting the 
aggregation of full-length tau. However, further characterization using different 
biochemical and biophysical methods is still required.  
Our selected peptides MMD3 and MMD3rev present promising candidates for 
therapeutic and diagnostic applications in AD research. Currently, MMD3 and 
MMD3rev are further characterized in the German Center for Neurodegenerative 














1   Introduction  
  
1.1   Alzheimer’s disease   
  
Alzheimer’s disease (AD) was first described as a presenile dementia more than 100 
years ago by the German psychiatrist Alois Alzheimer. AD is defined as a slowly 
progressing, irreversible neurodegenerative disease, associated with a progressive 
decline of cognitive functions (Alzheimer, 1907).  
In 2017, there were nearly 50 million individuals with dementia around the world, and 
4.6 million new cases are predicted to appear every year, implying 81.1 million cases 
by 2040 (Prince et al., 2013, World Health Organisation 2017). AD is the principle 
cause of dementia and accounts for 70 % of all cases (Anand et al., 2012; Galimberti 
and Scarpini, 2012). A person's risk of developing AD is about 10 -12 % (Bird, 1993). 
AD predominantly affects people over 65 and the risk reaches nearly 50% after age 85 
(Weuve et al., 2014; Zhao et al., 2014). Regardless of age, women are more likely to 
develop Alzheimer's disease (Farrer et al., 1997).  
To date, AD can be treated only symptomatically. As a result, AD symptoms ultimately 
necessitate nursing care. Indeed, more than 40 % of all places in German nursing 
homes are occupied by patients suffering from dementia (Bickel, 1996).  
  
1.2   Neuropathology of Alzheimer’s disease  
  
Alzheimer’s brains can be differentiated from healthy brains by a large loss in brain 
weight and volume associated with a shrinkage and loss of neuronal functions (Figure 
1a) (Gomez-Isla et al., 1996). In addition, AD brains have a significant atrophy of the 
hippocampus and the cortex, which is elevated sixfold comparing with normal elderly 
people (Fox et al., 2000; Fotuhi et al., 2009).  
AD is defined by two major neuropathological hallmarks, the extracellular deposition of 
amyloid plaques built by β-amyloid (Aβ) and the intracellular accumulation of 
neurofibrillary tangles (NFT) consisting of abnormally phosphorylated tau proteins (see 




These two protein aggregates share some biochemical characteristics. Both Aβ and 
tau form fibrils, which represent the main constituent of amyloid plaques (Aβ fibrils) and 
neurofibrillary tangles (tau fibrils). Both proteins undergo several post-translational 
modifications, such as phosphorylation, truncation and/or pyroglutamate in the brain of 
AD patients (Götz et al., 2001, Lasagna-Reeves CA et al 2010).   
 
Figure 1: Neuropathology of Alzheimer’s disease. (a) Brain of a healthy individual 
compared to the brain of a patient with severe Alzheimer disease. The mass and volume of 
the brain are significantly decreased in AD (National Institute of Aging 2015). (b) 
Photomicrograph of the temporal cortex of a patient with Alzheimer's disease (modified 
Bielschowski stain; original magnification, 400×). Two amyloid plaques (red arrows) with a 
neurofibrillary tangle (blue arrow) between them are shown (modified according to Perl, 2010; 
Dammers, 2015).  
  
1.3   The microtubule-associated protein tau  
  
Tau protein was first discovered in 1975 and was one of the first microtubule-
associated proteins (MAPs) to be identified (Weingarten et al., 1975). This started a 
research stream focused on the biological role of tau in microtubule-stabilization. Under 
pathological conditions, tau protein detaches the microtubules and forms aberrant 
filaments.  The loss of microtubule-stabilizing function of tau leads to axonal transport 
defects and synaptic dysfunction (Fig. 2) (Weingarten et al., 1975; Cleveland et al., 
1977; Binder et al., 1985)  
Healthy              Severe     
Brain                 AD  
  





Figure 2: Tau in healthy neurons and in tauopathies. (a) Tau directly binds to a microtubule 
(MT) within cells and stabilizes it, which dynamically regulates the structure and function of the 
MT. (b) Under pathological conditions; tau protein detaches the MT and assembles into 
filamentous structures that eventually form neurofibrillary tangles (NFTs). The loss of tau 
function results in MT instability and reduced axonal transport, which is a common feature in 
several neurodegenerative diseases, known as tauopathies, including Alzheimer’s disease 
(according to Brunden et al., 2009).  
  
  
1.3.1   Tau structure and characteristics  
  
Human tau is encoded by the MAPT gene on chromosome 17q21 (Neve et al., 1986). 
This protein is found mainly in the axons of the CNV (Central Nervous System) and 
comprises a family of six isomers produced by alternative splicing. Tau isomers range 
from 352 to 441 amino acids with apparent molecular weights between 45 and 65 kDa 
when run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
They differ by the presence or absence of regions encoded by exons 2, 3 and 10 





Figure 3: Schematic representation of the human tau gene, the human tau primary 
transcript and the six human tau isoforms. Chromosome 17 contains the human tau gene, 
which is located at position 17q21. There are six different tau isoforms, they differ by the 
presence or absence of one or two 29 amino acids inserts encoded by exon 2 (yellow box) 
and 3 (green box) in the amino-terminal section, together with either three (R1, R3 and R4) or 
four (R1–R4) repeat-regions (black boxes) in the carboxy-terminal section. The fourth 
microtubule-binding domain is encoded by exon 10 (slashed box) (lower panel). The adult tau 
isoforms are the longest 441-amino acid component (2+3+10+), the 410-amino acid 
component (2+3+10-), the 412-amino acid component de(2+3-10+), the 381-amino acid 
component (2+3-10-) and the 383-amino acid component (2-3-10+). The shortest 352-amino 
acid isoform (2-3-10-) is found only in the fetal brain, and hence is referred as fetal tau isoform 
(according to Buee et al., 2000).  
  
Tau proteins stabilize microtubules and promote their assembly by binding to the MT 
through a repetitive region in their Carboxy-terminal fragment, and hence the C-
terminal section is named the “binding domain”. The repetitive regions in the binding 
domain are the repeat domains (R1-R4) (Lee et al., 1989). In contrast, the amino-
terminal section does not bind to microtubules, projecting away from the microtubule 
surface. It is thus named the “projection domain”. The projection domain binds to other 
cytoskeletal elements and plasma proteins (Hirokawa et al., 1988)  
The overall amino acid composition of tau gives it the hydrophilic character. Due to its 
high solubility, normal tau protein does not form a folded structure. Indeed, evidences 
obtained from a variety of biophysical methods (e.g. NMR) reveals that the entire tau 






Figure 4: Schematic representation of the functional domains of the longest tau isoform 
(2+3+10+). The projection domain, which includes an acidic region and a proline-rich region, 
interacts with cytoskeletal elements. The C-terminal part, named the microtubule binding 
domain, binds to the MTs to stabilize them (according to Buee et al., 2000 with modifications).   
  
1.3.2   Tauopathies and the aggregation of tau protein   
  
The most apparent pathological event in several neurodegenerative diseases is the 
aggregation of tau isoforms into intraneuronal filaments. Under pathological conditions, 
monomeric tau self-assemblies and forms the small oligomeric tau species, which 
continue to accumulate and form filaments. In AD, these filamentous inclusions are 
named paired helical filaments (PHFs), PHFs subsequently form neurofibrillary tangles 
(NFTs) in neurons (Figure 5).  
  
Recent research findings suggest that large insoluble tau aggregates, such as 
filaments and tangles, do not appear to be the toxic species in neurodegenerative 
diseases. However, tau oligomers, pre-filament tau aggregates consisting of two or 
more tau molecules in a multimeric structure, are considered to be the key toxic form 
of tau in tauopathies. Furthermore, oligomeric tau species can be found in a 
hyperphosphorylated and an unphosphorylated form, and these oligomeric structures 
can be both soluble and insoluble. As the oligomers exist in such a variety of states, it 
becomes more challenging to understand their potential role in tauopathies (Cowan et 




Lasagna-Reeves et al. 2011 have demonstrated that tau oligomers are toxic in vitro 
and in vivo and reported that in vitro they cause much more cellular damage than tau 
monomers or fibrils.  
   
It was previously thought that the aggregation of tau in AD is due to the abnormal 
phosphorylation of tau proteins. However, normal tau protein is also phosphorylated in 
the brain and does not assemble into filaments. Furthermore, non-phosphorylated 
recombinant tau proteins aggregate into filaments under physiological conditions in 
vitro when polyanions (like heparin) are present. This suggests that several factors in 
addition to phosphorylation may cause the formation of pathological tau aggregates. In 
tauopathies, other mechanisms (e.g. ubiquitination, oxidation, glycation) may also play 




Figure 5: Schematic representation of the changes in tau leading to pathological 
aggregation. Under pathological conditions, the aggregation is initiated and tau-protein 
monomers self-assembly and form oligomers. The small oligomeric tau species are toxic. Tau 
oligomers continue to accumulate and form filaments (PHF), which eventually form the 
neurofibrillary tangles (NFT) characteristic of the disease (according to Guzmán-Martinez et 





1.3.3 The dominant role of PHF6 (VQIVYK) and PHF6* (VQIINK) in tau 
aggregation  
   
  
The insoluble aggregates of tau protein are involved in tau-related diseases, termed 
tauopathies, in which tau appears in an aggregated, chemically modified state 
(phosphorylation, oxidation, and glycation). Experimental aggregation studies, as well 
as computer simulations, have shown that tau aggregation is also strongly driven by 
two hexapeptide fragments, namely PHF6 (VQIVYK) and PHF6* (VQIINK). In vitro 
studies have revealed that short tau peptides containing PHF6 or PHF6* can aggregate 
and form fibrils (Pickhardt et al., 2004).  
The PHF6 segment is located at the start of the third repeat (R3) and is present in all 
tau isoforms. In contrast, the PHF6* segment is located at the start of the second repeat 
(R2) and is present only in four-repeat (4R) tau isoforms (Figure 6) as it is encoded by 
an alternatively spliced exon 10 sequence (Eschmann et al., 2015).  
  
 
Figure 6: Diagram of the MTBR showing the location and sequence of the two 
hexapeptide units (PHF6* and PHF6). The full-length four-repeat (4R) tau consists of 441 
amino acids, the longest isoform in the human central nervous system. This isoform has a 
projection domain as well as four repeats in the microtubule binding repeat region (MTBR). 
The PHF6 segment is located at the beginning of the third repeat (R3) and the PHF6* segment 
is located at the beginning of the second repeat (R2) (Eschmann et al., 2015).  
  
Until recently, it was thought that PHF6, 306-VQIVYK-311, is the most potent driver for 
tau assembly into paired helical filaments (PHF), and that mutations in this six-residue 
segment could decrease or increase the aggregation of tau. Furthermore, the PHF6 




like heparin and forms fibrils similar to full-length tau fibrils. In silico studies on the PHF6 
self-aggregation fragment found a zipper-like arrangement of the amino acid residues 
owing to hydrophobic stabilization (von Bergen et al. 2000; Goux et al. 2004; Ganguly 
et al., 2015). However, in 2018, Seidler et al. suggested that the VQIINK segment 
(PHF6*) is the more powerful driver of tau aggregation (Seildler et al., 2018).  
  
  
1.4   Diagnosis of Alzheimer’s disease  
  
1.4.1   Current diagnostic methods  
  
The diagnosis of Alzheimer’s disease (AD) is so challenging and the definitive 
diagnosis requires post-mortem examination of brain tissue. The current diagnosis of 
AD is based mainly on patient interview, disease history, clinical neuropsychological 
examination, and identification of typical symptoms of AD. As AD is associated with a 
large loss in brain weight and volume, a brain scan, using either computed tomography 
(CT) or magnetic resonance imaging (MRI), is recommended in the standard 
evaluation of AD. Both CT and MRI scans can reveal the loss of brain mass associated 
with AD.  Other brain scans, such as Positron emission tomography (PET) can also be 
performed. While CT scans and MRIs can only reveal changes in later stages of the 
disease and are unable to detect problems at the cellular level, PET scans are able to 
detect early pathological cellular changes (McKhann et aI., 1984; DeCarli et aI., 1990).  
Although Aß and tau are both considered key biomarkers in AD and correlate with 
disease progression, latest development in radiological imaging have allowed the 
detection of AD pathological biomarkers using PET. Over the past decade, the 
development of non-invasive diagnostic neuroimaging markers for AD lead to increase 
the diagnostic accuracy in AD. Most notably, molecular imaging of brain amyloid by 
PET imaging using radiotracers that label fibrillar forms of amyloid-β. Patients are 
injected with a radiolabelled tracer agent and undergo a specialized PET scan, which 
detects the aggregation of amyloid-β peptides into plaques in the living brain. At the 
present time, 18F-labeled amyloid radiotracers (18F-florbetapir, 18F-florbetaben, and 18F-




practice, using of amyloid PET imaging is still limited because of its high cost for most 
patients (McKhann et al., 2011; Laccarino et al., 2017; Weller et al., 2018).  
Moreover, AD biomarkers can be detected in the cerebrospinal fluid biomarker (CSF) 
of AD patients. Aβ42, total tau (t-tau) and phosphorylated tau (p-tau) have been the 
focus of biomarkers research due to the direct correlation with pathological hallmarks 
(Tapiola et al., 2009). Many studies have demonstrated an increase of approximately 
300% in the concentration of t-tau in AD patients compared to normal elderly 
individuals. In several studies, elevated p-tau levels have also been detected in the 
CSF of AD patients in comparison to controls, with sensitivity and specificity of between 
80 and 90% (Biagioni et al., 2011). However, there is high inter- and intra-laboratory 
variation so the classical cut-off of pathological levels varies between laboratories 
performing the same method. Another limitation of this method, that CSF-levels of AD 
biomarkers are altered in diabetic and prediabetic patients (Lu et al., 2018; Bogdanovic 
et al., 2018)  
  
1.4.2   Diagnostic methods under investigation  
  
Despite the hypothesis that Aß accumulation is the primary cause of AD, studies have 
shown that the pathological changes in tau correlate more closely with cognitive 
changes and disease progression. Therefore, detecting pathological changes in tau 
provides attractive targets for novel diagnostic strategies (Wu et al., 2017). PET-tau is 
under intense development and several tau tracers have been developed and tested 
in human PET studies. Currently available tau tracers fall into 4 groups: the 
nonselective tracer 18F-FDDNP, quinoline derivatives, pyrido‑indole derivatives, and 
phenyl/pyridinylbutadienyl‑benzothiazoles/benzothiazoliums derivative (PBB3). These 
promising tau-specific PET tracers are now available for clinical evaluation and present 
a major breakthrough in AD research (Saint-Aubert et al., 2017).   
  
Detection of plasma biomarkers in blood plasma could enable a minimally invasive test. 
Recent studies on plasma levels of Aß as a marker for AD demonstrated that brain 
amyloid positivity could be accurately evaluated using one blood sample. Studies have 
reported increased t-tau levels in the plasma of AD patients. However, several 




dementia are also being developed. This may facilitate the detection of tau oligomers 
or other tau species, which play a key role in tau aggregation (Biagioni et al., 2011, 
Bateman et al., 2019).  
1.5   Therapeutic strategies of Alzheimer’s disease  
  
1.5.1   Current medication therapies  
  
Despite all scientific efforts, there is still no curative treatment for AD. Currently, there 
are four medications available for the treatment of AD. Three cholinesterase inhibitors 
(CIs) donepezil, rivastigmine, and galantamine. These drugs inhibit the enzymatic 
breakdown of acetylcholine, a neurotransmitter that is responsible for cognitive function 
in the brain, and increase its concentration. The fourth drug is memantine. Memantine 
is an N-methyl-d-aspartate receptor antagonist that blocks the effect of glutamate, a 
neurotransmitter in the brain, by preventing its binding to the target receptors. This 
protects neurons from excitotoxicity and prevents neuronal cell death, which may 
reduce behavioral and psychological symptoms of AD. However, all established 
treatments are only symptomatic, they slow down the disease progression and can 
delay the symptom, but they do not significantly improve cognitive function or cure the 
disease (Wenk et al., 1995; Rogers et al., 1998; Parsons et al. 1999; Reisberg et al., 
2006).   
  
1.5.2   Current research and possible future treatment  
Therapies under study are compounds that target the pathological biomarkers of AD: 
extracellular amyloid β (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) 
(McKhann et aI., 1984).  
Although it is still controversial if Aβ is the causative protein leading to AD, AD therapy 
research has been predominantly focused on “Amyloid hypothesis” and several 
Alzheimer's therapeutics have been developed by targeting amyloid beta peptide. Aß-
related therapeutic strategies involve, decreasing the production of Aß or enhancing 
its clearance. However, the literature provides major arguments for and against the 
amyloid hypothesis. It seems likely, that Aβ is key initiator of AD and amyloid plaques 




to treat AD have not succeeded and the recent research suggests that the main driver 
of AD is tau, not Aβ (Kametani et al., 2018).  
It has been also considered controversy whether tau hypothesis is the primary 
causative of AD or plays more a secondary role. However, candidate drugs targeting 
tau currently seem to be the most promising strategy for AD drugs development (Frost 
et al., 2015). Here, an overview of the principal strategies targeting tau in AD, as 
described in the literature, is provided.  
Modulating tau phosphorylation  
Due to the correlation between tau phosphorylation and AD pathology, tau-protein 
kinase inhibitors constitute potentially useful treatments. In fact, tau 
hyperphosphorylation in vivo seems likely due to multiple protein kinases. Precisely 
which kinase is the most effective target to minimize pathological tau phosphorylation 
remains an open question (Wang et al., 2007; Zhang et al., 2013). Many protein 
kinases, such as GSK-3β, MARK, and CDK5, have been considered as attractive AD 
therapeutic targets. However, therapeutic agents that modulate tau phosphorylation, 
such as Tideglusib and Lithium (available GSK-3β inhibitor), have not demonstrated 
clinical benefit to date (Anand and Sabbagh, 2015; Lovestone et al., 2015; Medina, 
2018).  
Microtubule stabilizers  
Another tau-targeting therapeutic strategy in neurodegenerative diseases is stimulating 
microtubule stabilization. As is known that detachment of tau from microtubules causes 
loss of tau MT-stabilizing function, resulting in the suggestion that MT-stabilizing 
molecules could be used as therapeutic agents. Among such MTstabilizing molecules, 
which has reached an advanced clinical phase, is davunetide (also known as NAP). 
Davunetide is an eight-amino acid peptide that has shown promising effects in tau 
transgenic mice, but later clinical trials in AD patients ended in failure (Matsuoka et al., 
2008; Boxer et al., 2014).  
Anti-tau immunotherapy  
Anti-tau immunotherapy for several neurodegenerative disorders represents a 




active immunotherapy strategies utilize specific antibodies that bind to pathological tau, 
leading to a clear up of tau pathological species and a potential improvement in 
neuronal function (Huang and Mucke, 2012). Studies have reported a reduction in 
filamentous tau inclusions in transgenic mice by active immunization targeting 
phosphorylated tau (Asuni et al., 2007). The clearance mechanism of intracellular 
proteins, such as tau, by immunization is still unknown, but it may involve lysosomal 
proteolysis and autophagy of tau-antibody complexes (Sigurdsson, 2009). To achieve 
a successful immunotherapy approach, it is important to identify the correct epitopes 
and conformations that differentiate between physiological and pathological tau. In 
summary, a number of anti-tau immunotherapy are already in clinical trials such as 
ABBV-8E12, BIIB092, AADvac-1 and ACI-35 (Medina, 2018).  
Tau aggregation inhibitors  
As tau aggregation correlates with clinical Alzheimer disease progression, the inhibition 
of tau aggregation could protect the damaged neurons. Several tau aggregation 
inhibiting substances have been described in the literature. Methylene blue, which 
inhibits tau–tau interactions and reduces soluble tau through other mechanisms, has 
shown promising results in terms of delaying disease progression in a phase II clinical 
trial carried out of the course of one year. Clinical phase III trials with an optimized 
formulation of methylene blue (LMTX) are in progress to investigate the potential of 
LMTX in slowing the progression of the disease in AD patients (Gura, 2008; Huang 
and Mucke, 2012; Jadhav et al., 2019). Several chemical compounds that inhibit tau 
fibril formation have been identified, including phenothiazines (Wischik et al., 1996) 
anthraquinones (Pickhardt et al., 2005), polyphenols (Taniguchi et al., 2005), 
quinoxalines (Crowe et al., 2007) and phenylthiazolyl-hydrazides (Pickhardt et al., 
2007). However, excluding the phenothiazine methylene blue, none of these molecules 
has been tested in vivo, and most of the compounds described above have biochemical 
characteristics that likely render them unsuitable as CNS-targeted therapeutics (Crowe 







1.6   D-peptides for therapy and diagnosis of Alzheimer’s disease  
  
The use of small D-peptides for diagnosis and therapy of AD by may represent a 
reasonable alternative to chemical pharmaceuticals. Peptides are specified as (linear) 
molecules consisting of two or more (<100) amino acids. D-enantiomeric peptides are 
extremely protease resistant, which extends their period of biological activity and 
renders them prime candidates for the development of therapeutic drugs. D-peptides 
are considerably less immunogenic than L-peptides and their suitability for in vivo 
applications has been confirmed. In addition, studies showed systemic absorption of 
therapeutic D-peptides after oral administration (Milton et al., 1992; Pappenheimer et 
al., 1994; Pappenheimer et al., 1997; Chalifour et al., 2003; Funke et 2010). Therefore, 
small peptides that bind to Aβ or tau and influence aggregation are of particular interest.  
Several small peptides that prevent aggregation of Aβ have already been described 
and some of them have been shown to be effective in AD animal models. In addition, 
Aβ binding peptides have been developed for use in in vivo imaging methods for 
possibly early diagnosis of AD. Using mirror image page display method, the group of 
Willbold in Germany identified D-Peptide D3 (rprtrlhthrnr). D3 disassembles Aβ 
aggregates and reduces the amyloid plaque burden in APP/PS1 double transgenic 
mice. It has been demonstrated that D3 peptide, when injected or infused into animal, 
did not cause an inflammatory response and was able to bind to Aβ1–42 in the brains 
of transgenic mice. Furthermore, it has been shown that D3 is taken up by neurons. 
Oral treatment with D3 led to an improvement in pathology and behavior in APP/PS1 
double transgenic mice, indicating that the peptide is capable to cross the blood brain 
barrier using transcytosis. Recently, D-enantiomeric peptide RD2, derived from D3 by 
rational design, was successfully tested in a phase I clinical study (van Groen et al., 
2008; van Groen et al., 2009; Funke et al., 2010; Leithold et al., 2016; Klein et al. 2016; 
Kutzsche et al., 2017; van Groen et al., 2017; Elfgen et al. 2019; Willbold and Kutzsche; 
2019).  
As it previously mentioned, the majority of existing AD therapeutic research has 
focused on Aβ. However, to date little research has been directed towards the 
development of tau-targeted peptides.   
In 2011, the Eisenberg group developed a D-amino acid inhibitor of tau fibril formation 




interact favorably with the 306-VQIVYK-311 segment on tau (PHF6). It has been 
demonstrated that VQIVYK plays a crucial role in tau fibrillization and is commonly 
used as a model for tau fibrillization. The designed peptide, TLKIVW, inhibits the 
aggregation of PHF6 as well as of the tau constructs K12 and K19 (Sievers et al., 
2011).  
In 2016, a study by our group showed a modulation of the tau aggregation mechanism 
by 12 amino acid D-enantiomeric peptides (Dammers et al., 2016). Mirror phage 
display selections were conducted using fibrils of the D-enantiomeric PHF6 as a target. 
The study showed that PHF6 binding D-enantiomeric peptides APT, KNT, LPS, TD28, 
and TD28rev, selected by mirror image phage display, inhibit PHF6 and full-length tau 
fibrillization. Furthermore, the selected peptides were able to penetrate tau expressing 
N2a cells.  
  
In a very recent study in 2018 by the Eisenberg group, the authors hypothesized that 
PHF6* is a more powerful driver for tau aggregation than PHF6, and that inhibitors 
based on the structure of PHF6 fragment only partially inhibit the fibrillization of full-
length tau. Using PHF6* segment as a template, they designed structure-based 
inhibitors that inhibit seeding by tau fibrils in a concentration-dependent manner. The 
most promising designed peptide, named as W.MINK, showed its ability to inhibit the 
aggregation of full-length tau in THT assays. In addition, W.MINK was able to block the 
seeding of intracellular tau, induced by exogenous tau40 fibres, in HEK293 biosensor 
cells (Seidler et al., 2018).   
  
  
1.7   Phage display as a tool for drug discovery  
  
Phage display technology constitutes an important approach for discovering novel 
target-specific ligands for proteins. Antibodies and peptides are expressed on a phage 
surface and used for target screening. In 1985, phage display was discovered by 
George P. Smith after he demonstrated the display of fusion proteins on the virion 
surface (Smith, 1985). Phage display has been widely used in many therapeutic and 
diagnostic approaches as a result of its economical, rapid, and effective properties 





A bacteriophage (phage) is a virus that infects bacteria. There are three types of 
bacteriophage; filamentous, lambda and T7 phage. The filamentous phage family 
includes three strains M13, f1 and fd (Salivar et al., 1964; Smith, 1985). The M13 phage 
is commonly used for phage display (Huang et al., 2012). Foreign DNA fragments can 
be inserted into a phage gene to encode a fusion protein, leading to physical linkage 
between the DNA sequence and the peptide sequence. Ph.D. peptide library series 
(New England BioLabs, Inc., USA) is the most widely used peptide library, in which the 
displayed peptides (12-mer) are fused to the minor coat proteins (pIII) (Parmley and 
Smith, 1988; Qiang et al., 2017).   
  
A typical phage display peptide library contains a large number of phage particles (a 
population of > 1012 phage clones), whereby each displays a different peptide. 
Therefore, biopanning, a procedure to select specific binders, is essential to enrich the 
desired binding molecules. The target molecule is immobilized on a solid support such 
as microtiter plate wells (Watters et al., 1997). Phages from the library are added to 
the immobilized target. Nonbinding clones are washed away and clones bound to the 
target are eluted by different strategies. The eluted bound phages are amplified in 
E.coli and used for the next round of biopanning to re-select bound phages (see Figure 
7). Several rounds of biopanning are necessary in a screening procedure until the 
phage pool is enriched with specific binding phages. For determining the binding 
activity of obtained monoclonal phages, tests are used, for example an enzyme-linked 
immunosorbent assay (ELISA). The sequence of the binding peptides is identified by 
sequencing of the phage DNA encoding the peptide (Cwirla et al., 1990; Scott and 
Smith, 1990).  





Figure 7: The principle of the phage display system for the selection of peptides binding 
to an immobilized target. A phage library is incubated on a target-coated surface, followed 
by extensive washing to remove non-specific phages. Subsequently, bound phages are eluted 
and amplified in E.coli. The amplified phages are used for the next round of biopanning to 
reselect bound phages. After several selection rounds (3-4), individual bound phage clones 
are isolated. ssDNA of the phages clones are extracted and after sequencing, the peptides 
sequences are identified (Huang et al., 2012).  
  
Phage display and its application is the subject of many patents, and therapeutic 
products developed by this technology are available on the market (Bazan et al., 2012). 
However, despite the success of many phage display selections and the discovery of 
strong binders for several targets, confused results can be obtained. Phages with no 
actual affinity to the target may be selected, instead of specific ligands (Vodnik et al., 
2011). The obtained peptides that bind to other components of the screening system 
and do not exhibit specific affinity to targets are named target-unrelated peptides 
(TUPs) (Menendez and Scott, 2005). However, several freely accessible tools 
compare each sequence with their database and assist in the reporting and excluding 
of possible target-unrelated peptides (Vodnik et al., 2011; Qiang et al., 2017). 
 





1.7.1   Mirror image phage display   
  
The main disadvantages of peptides selected from biologically encoded libraries are 
their short half-life in vivo as a result of fast degradation by enzymes, and their ability 
to trigger an immune response. Thus, Schumacher and co-workers developed an 
elegant approach in 1996, termed the mirror image phage display, which allows the 
peptides identification in the D-conformation (Dintzis et al., 1993; Schumacher et al., 
1996).  
In a common phage display approach, an L-peptide library is expressed on the surface 
of the phages and bind to the L-enantiomeric form of the immobilized target protein. By 
employing mirror image phage display, the biopanning is performed against the mirror 
image of the original protein target, which is composed of the same amino acid 
sequence but in unnatural D-enantiomeric form (see Figure 8). A cause of the 
symmetry, the synthesized D-enantiomeric form of the selected peptides will bind to 
the L-enantiomeric form of the target protein. The D-enantiomeric peptides have many 
advantages over L-peptides. Mainly, they have a long serum and salvia half-live due 
to their resistance to proteases. Furthermore, while L-peptides should be injected to 
avoid digestion, D-peptides can be absorbed into the systemic circulation following oral 
administration (Milton et al., 1992; Pappenheimer et al., 1994; Chalifour et al., 2003; 
Sadowski et al., 2004). However, mirror image phage display can be performed against 
target proteins which fold spontaneously and do not require molecular chaperones for 
functional folding. Because it is not clear if the natural chaperones can fold the D-form 
of the protein or D-form of the chaperon is required (Weinstock et al., 2014). 
A number of mirror image phage display approaches used for the selection of D-
peptides seemed to be interesting and promising for the diagnosis and therapy of 
Alzheimer’s disease.  D-enantiomeric peptide D3 was selected, in a mirror image 
phage display, against monomeric and small oligomeric D-Aß peptide as a target. D3 
showed promising results in Alzheimer's transgenic mice after oral treatment (van 
Groen et al., 2008). In addition, a study by our group (Dammers et al., 2016) identified  
PHF6 binding D-enantiomeric peptides, using mirror image phage display, that inhibit 
PHF6 and full-length tau fibrillization in vitro. Moreover, the selected peptides were able 







Figure 8: The principle of phage display and mirror image phage display. In phage 
display, the L-enantiomeric form of the protein-target is used and the L-peptides that bind to 
the target are selected. The selected L-peptides have the disadvantages that they are 
immunogenic and protease-sensitive. In mirror image phage display, the D-enantiomeric form 
of any protein-target is synthesized and used for the selection. The L-peptides that bind to the 
D-enantiomeric target, are selected. The D-enantiomeric form of the selected L-peptides are 
synthesized. These synthesized D-peptide will bind to the L-enantiomeric form of the target. 
The D-peptides have many advantages comparing with L-peptides. Mainly, they are non-














2     Objective of the thesis   
  
To date no curative drug for AD has been developed, and those therapies that are 
currently available can only delay the progression of the disease. Therefore, there is a 
need for novel diagnostic and therapeutic approaches for AD and the recent research 
suggests that targeting tau pathology represents a promising lead in this regard.  
In this project, the main aim was to develop novel therapeutic D-enantiomeric peptides 
that target tau protein using both phage display and mirror image phage display. D-
enantiomeric peptides were chosen as they are stable against protease and 
considerably less immunogenic than L-peptides (Schumacher et al., 1996; Chalifour et 
al., 2003; Sadowski et al., 2004). Another aim of this study was to investigate which of 
the both fragments within tau, PHF6 or PHF6*, is likely the more effective target for the 
development of tau aggregation inhibiting peptides.  
First, large quantities of tau protein were needed for this project. Thus, it was necessary 
to establish a method for expression and purification of full-length tau protein.  
Next, the first phage display selection was performed against the L-enantiomeric full-
length tau monomer. The selected L-peptides were synthesized as D-peptides. In 
addition, using mirror image phage display, the second selection was performed 
against the fibrils of the D-enantiomeric hexapeptide 275-VQIINK-280 (PHF6*), 
representing residues 275–280 of the tau protein.  
The selected peptides from both selections were characterized by Thioflavin T (THT) 
assays in order to determine whether they can modulate pathological tau aggregation 
in vitro.   
The ability of the selected peptides to bind to tau monomers, tau fibrils, PHF6 fibrils 
and PHF6* fibrils was tested using ELISA (Enzyme-Linked Immunosorbent Assay). To 
enable the use of this method, FAM-labeled versions of the peptides were synthesized.   
Also, we performed early preliminary experiments to investigate the hypothesis that 
PHF6* is the superior target for inhibitors of pathological tau aggregation. The tau 
aggregation inhibiting effects of the most promising peptides resulting from this project, 




was selected against PHF6 fibrils earlier by our group. As controls, we further tested 
the performance of two peptides previously described in the literature, TLKIVW and 
































3     Material and Methods  
  
3.1   Material  
  
Unless otherwise stated, all chemicals and reagents were purchased from Bio-Rad 
Laboratories GmbH (München), Carl Roth GmbH + Co. KG (Karlsruhe), GE Healthcare 
(Freiburg), Merck Chemicals GmbH (Darmstadt), New England BioLabs GmbH (NEB; 
Frankfurt a. M.), Sigma-Aldrich Chemie GmbH (Taufkirchen), Thermo Fisher 




3.1.1   Antibodies   
  
The antibodies listed below were aliquoted upon arrival and frozen at -20 °C.  
  













(primary antibody)  
Human protein 
tau  




(primary antibody)  
Bacteriophage 
M13  
ELISA  27-942101   
  

















Mouse species  WB  A90616AP   
  
Bethyl Lab.,  
Inc.,   












Genotype  application  manufacturer   
  
E. coli BL21 
(DE3)  
F– ompT gal dcm lon 
hsdSB(rB-mB-) λ(DE3 [lacI 
lacUV5-T7 gene 1 ind1 
sam7 nin5 ])  
gene expression  Life  
Technologies,  
Darmstadt  
E. coli ER2738  F´ proA+ B+ lacIq  
Δ(lacZ)M15  
zzf::Tn10(TetR)/fhuA2 
glnV Δ(lac-proAB) thi-1  
Δ(hsdS-mcrB)5  
phage display  New England 
BioLabs, Ph.D.  
Phage Display  
Libraries Kit,  
Frankfurt a. M.  
  
3.1.3   Plasmids and primers  
  
plasmid  insert  vector  manufacturer  
pET28a(+)_tau 441aa  Full length human tau 
protein 2N4R  
pET28a(+)  Genentech (San 
Francisco)  
  
primer  sequence  manufacturer  
-96 gIII sequencing 
primer  
5´- GTATGGGATTTTGCTAAACAAC–3´  Sigma-Aldrich  
  
  
3.1.4   Peptides  
  
All peptides used in this thesis are listed in Table 1 and Table 2. All peptides were 
purchased from JPT Peptide Technologies GmbH (Berlin). The company provided 
HPLC-purified lyophilisates with a stated purity of > 95 %. The peptides were stored at 
-20°C.  









Table 2: List of synthetic peptides  
name   amino acid sequence   
  
chirality   
  
PHF6  VQIVYK  L  
PHF6*  VQIINK  L  
PHF6*  vqiink  D  
Sievers  tlkivw  D  
APT  aptllrlhslga  D  
W.MINK  DVWMINKKRK  L  
  
Table 3: List of synthetic peptides selected during this thesis   
name   amino acid sequence   
  
chirality   
  




GSWNTFRAQPTI   
  
L  Tau monomer  
MM2  
  
LTPHKHHKHLHA  L  Tau monomer  
MM3  
  
DPLKARHTSVWY  L  Tau monomer/  






























D  Tau monomer  
MMD2rev   
  
ahlhkhhkhptl  
    
D  Tau monomer  
MMD3  
  
dplkarhtsvwy  D  Tau monomer/  
 PHF6* fibrils  
MMD3rev   
  
ywvsthraklpd  D  Tau monomer/  




MMD2-Lys(FAM)-NH2   LTPHKHHKHLHA-
Lys(FAM)NH2   
  
D  Tau monomer  




D  Tau monomer/  
 PHF6* fibrils  









L  PHF6* fibrils  




L  PHF6* fibrils  
MMP4  
  
HPAPHRYHSNLH  L  PHF6* fibrils  
MMP5  
  
TRTATLADNSWL  L  PHF6* fibrils  
MMP6  
  
HSDLWRRSFELM  L  PHF6* fibrils  
MMPD2  
  
wphdtkrylfpa  D  PHF6* fibrils  
MMPD6  
  
hsdlwrrsfelm  D  PHF6* fibrils  
  
3.1.5   Buffers, media and kits  
All used buffers, solutions and media are listed in Table 4; they were prepared in 
distilled, deionized water. All kits used are listed in Table 5.   
  
Table 4: List of buffers and media.  
description   
  
composition  
Blocking buffer  
(ELISA)  
0,1% (w/v)  bovine serum albumin 
in 0.1 M NaHCO3 buffer, pH 8.6   
 
Blocking buffer (phage 
display)  
 5 mg/mL bovine serum albumin   
in 0.1 M NaHCO3, pH 8.6  
 sterile filtered  
Blocking buffer (WB)   1x TBS   
 0,05% Tween-20   




Buffer A  20 mM HEPES  pH 
6.8  
Buffer B  20 mM HEPES  
1 M NaCl  pH 
6.8  
Calcium chloride  
(CaCl2) buffer  
 50 mM, pH 9,0  
Coomassie brilliant 
blue staining solution  
0,25% coomassie blue R250   
50% methanol   
10% acetic acid  
 
destaining solution  9% methanol   
9% acetic acid  
9% glycerine  
Heparin stock solution  1 mM heparin in ddH2O  
IPTG stock solution  500 mM in H2O, sterile filtered  
IPTG/Xgal  5 g/l IPTG  4 g/l 
Xgal  in 
Dimethylformamid  
IPTG/Xgal/LB plates  1 ml from IPTG/Xgal stock solution for 1 l LB-agar  
Kanamycin   50 mg/ml in H2O, sterile filtered;  
used concentration: 50 µg/ml  
LB-Agar  1,5% (w/v) Agar-Agar in LB medium  
LB medium  1% (w/v) Trypton    
0,5% (w/v) Hefeextrakt   0,5% 
(w/v) NaCl  




Lysis buffer  20 mM HEPES   
1 mM EDTA   
2 mM Proteaseinhibitor   
2 mM 2-Mercaptoethanol                         
pH 6.8  
0.5 M Napi-buffer  
(sodium phosphate)   
0.5 M Na2HPO4 pH 9 0.5 
M H2NaPO4 pH 4  
Mix the solutions to final pH 7  
1x PBS   1,37 M NaCl   
 27 mM KCl    
 14 mM KH2PO4   
 100 mM Na2HPO4 in ddH2O, pH 7.5  
PBST  1x PBS   
0,01% (v/v) Tween-20  
 PefaBlock  stock  
solution  
200 mM in sterile ddH2O  
PEG/NaCl  20% (w/v) polyethylene glycol–8000  
2.5 M NaCl, autovlaved  
10x SDS running    
buffer  
25 mM Tris   
192 mM glycerine 
0,1% (w/v) SDS  pH 
8,3  
4x SDS sample  
buffer  
40% (v/v) glycerine  
250 mM Tris-HCl, pH 6.8   
8% (w/v) SDS   
0,015% (w/v) Bromophenol blue   
20% (v/v) β-Mercaptoethanol    
1x TBS (WB)  20 mM Tris-HCl, pH 7.5   
150 mM NaCl  
1x TBS (phage 
display)  
50 mM Tris-HCl, pH 7.5   




Tetracyclin  20 mg/ml in 1:1 EtOH:H2O; used concentration:  
20 µg/ml  
Thioflavin T stock  
solution  
1 mM thioflavin T in ddH2O  
Top-Agar  7 g/l Agar-Agar in LB-medium 
autoclaved  
1x Transfer buffer  25 mM Tris  192 
mM Glycine  pH 
8.3    
Washing buffer  
(ELISA)  
1x PBS   
  1% (v/v) Tween-20  
Washing buffer  
(WB)  
1x TBS   
0,05% (v/v) Tween-20  




Table 5: List of used kits.  
description   
  
manufacturer   
  
Ph.D.-12 Phage Display Peptide Library Kit   
  
New England BioLabs, Frankfurt a.M.  
Pierce™ 660nm Protein Assay Kit  Thermo Fisher Scientific, Darmstadt  
  
TMB Peroxidase EIA Substrate Kit   
  
Bio-Rad Laboratories, München   
  




3.2    Microbiological methods  
  
3.2.1   Calcium chloride method for preparation of chemical competent cells  
Chemical competent cells were prepared by inoculation of 100 ml LB medium with one 




of 120 rpm. The next day, 200 ml LB medium were inoculated with 20 ml of overnight 
cell culture and incubated at 37 °C with 140 rpm shaking until OD600 ≥ 0.6 was reached. 
The cells were harvested by centrifugation for 20 min at 4000x g and 4°C. The 
supernatant was discarded, the pellet was resuspended in 20 mL ice-cold 50 mM 
CaCl2 buffer and incubated on ice for 30 min. The cells were separated by 
centrifugation for 10 min at 4 °C and 4000x g. Finally, the pellet was resuspended in 
10 mL ice-cold CaCl2 50 mM solution and incubated for 15 min on ice. Bacterial 
glycerol stocks were prepared by adding sterile glycerol to a final concentration of 25 
% and the cell suspension was portioned into 200 µL aliquots. The chemical competent 
cells were stored at -80 °C.  
  
3.2.2   Heat shock transformation of DNA into chemically competent cells  
The plasmid pET28a(+)_tau441aa was transformed into the chemically competent 
cells E. coli BL21 (DE3) via heat shock. The cells were thawed on ice, 1 µg of the 
plasmid DNA was added and they were incubated on ice for 15 min. The cells were 
heated up to 42 °C for 90 seconds and then cooled on ice for 2 min. The transformed 
cells were filled up to a total volume of 1 mL with LB media and incubated for 1 hour 
(h) at 37 °C and 130 rpm. The cells were plated out onto agar plates including 
kanamycin at a concentration of 50 µg/ml in two steps of 200 and 800 µL, respectively.  
The plates were incubated overnight at 37 °C.  
  
3.3   Molecular biological methods  
3.3.1   Expression of recombinant human tau protein  
One transformed colony was picked from the kanamycin agar plate, inoculated into 50 
ml LB containing 50 µg/ml kanamycin. This culture was allowed to grow overnight 
under shaking (130 rpm) at 37°C. The following morning, 1 L main culture LB media 
containing 50 µg/mL Kanamycin, 0.5 % glucose and 10 mM MgCl2 was inoculated with 
10 ml overnight culture and divided into 2 different 2 L shaking flasks filled with 500 mL 
volume. The culture was incubated at 37 °C and 150 rpm until an extinction at 600 nm 
wavelength OD600 ≥ 0.6 was reached. Subsequently, tau expression was induced by 




rpm, cells were pelleted by centrifugation at 4000x g for 20 min at 4 °C. The resulting 
pellet was then resuspended in 14 ml of lysis buffer and immediately stored at -20°C 
until further use.  
To check for successful tau expression, 1 ml of uninduced and induced samples were 
aliquoted and centrifuged for 1 min at 14000 rpm. The resulting pellets were suspended 
in 4x SDS sample buffer (200 µl for one unit of OD600). The samples were boiled at 95 
°C for 5 min and analyzed using SDS-PAGE.  
  
3.3.2   Extraction of recombinant tau protein  
  
The frozen resuspended cell pellet was thawed on ice, the cell lysate was pipetted into 
a fresh falcon tube and boiled for 10 min. Through this boiling treatment, most of the 
proteins are denatured apart from tau, which remains in solution preserving its 
physiological function. After cooling the boiled cell lysate on ice for 10 min, the 
denatured proteins were removed by centrifugation at 4°C, 5000x g for 1 h. The 
supernatant containing tau protein was taken for further purification. 20 µl were taken 
from the supernatant and prepared for SDS-PAGE analysis.  
  
3.4   Protein chemical methods  
  
The purification of the tau protein was performed according to two protocols; the first 
was a modified version of that described by Margittai et al., 2004 and the second was 
a modified version of that described by KrishnaKumar et al., 2017. In the first protocol 
(Margittai et al., 2004), various purification methods were used such as ammonium 
sulfate precipitation, anion exchange chromatography and cation exchange 
chromatography. The high purified tau protein obtained from this method was used for 
the phage display selection. In the purification method reported by KrishnaKumar et 
al., 2017, they established a simplified protocol for efficient extraction in which tau 
lysate was purified by cation exchange chromatography. The purified tau protein 





3.4.1   Ammonium sulfate precipitation  
  
Ammonium sulfate precipitation was carried out on ice to avoid protein degradation. 
Ammonium sulfate was added to the protein solution until a saturated solution of 50% 
concentration was obtained. The solution was allowed to precipitate overnight at 4°C. 
The precipitated proteins were collected by centrifugation. The pellet was dissolved in 
distilled water including 5 mM DTT and stored at 4 °C.  
  
3.4.2   Cation exchange chromatography  
  
The prepacked column HiTrap SP FF (GE Healthcare, Freiburg) was used. The column 
is packed with SP Sepharose Fast Flow, which is a negatively charged matrix, so the 
positively charged protein tau can bind to the column and a cation exchange can be 
performed. The column was equilibrated with buffer A according to the instructions 
supplied with the column.  The sample, which contained the tau protein, was loaded 
into the column with flow rate 1 ml/min. After two washing steps with five-column 
volume (CV), tau protein was eluted by increasing the salt concentration, 0.1 M – 0.7 
M NaCl in buffer A, using stepwise gradient elution. Fractions of 4 ml were collected.  
20 µl samples from each fraction were taken for SDS-PAGE analysis.  
3.4.3   Anion exchange chromatography  
  
The positively charged Q sepharose Fast Flow (GE Healthcare, Freiburg) was used as 
a matrix. 2 ml of the slurry was prepared according to the manufacturer's instructions 
and transferred to a fritted column. After washing the slurry with an HEPES buffer, the 
fractions containing tau were loaded onto the column and the run was started with a 
flow rate of 1 ml/min. The flow through containing the tau protein was then collected.  
  
3.4.4   Ultrafiltration  
  
The samples containing recombinant tau protein were concentrated via ultrafiltration.  
Amicon® Ultra-15 centrifugal filter unit (Merck KGaA, Darmstadt) with a mass weight 
cut-off (MWCO) of 10 kDa was equilibrated with buffer A by centrifugation at 4000 x g, 
8 °C for 10 min. The samples were filled into the column and centrifuged at 4000 x g, 





3.4.5   SDS-Polyacrylamide-gel electrophoresis (SDS-PAGE)  
  
Protein samples were separated on standard 12% SDS-PAGE after mixing with 4x 
SDS sample buffer and heating at 95 °C for 5 min. The separating gel solution and the 
stacking gel solution were prepared according to Table 6 and Table 7 and poured into 
the gel cassette. A pre-stained protein ladder „Precision Plus ProteinTM Standard Dual 
Color“ (Bio-Rad, München) was used  
  
Table 6: Ingredients of 12 % SDS separating gel.   
Ingredients  Volume  
Acrylamid (30 %)  4 ml  
1,5 M Tris/HCl buffer pH 8,8 (Bio-Rad)  2,5 ml  
H2O  3,4 ml  
10 % (w/v) SDS solution  0,1 ml  
ammonium persulfate (APS) 10 % (w/v)  50 µl  




Table 7: Ingredients of 5 % SDS stacking gel.  
Ingredients  Volume  
Acrylamid (30 %)  0.85 ml  
1,5 M Tris/HCl buffer pH 6,8 (Bio-Rad)  1.25 ml  
H2O  2,85 ml  
10 % (w/v) SDS solution  50 µl  
ammonium persulfate (APS) 10 % (w/v)  25 µl  
TEMED  5 µl  
  
3.4.6   Coomassie Brilliant Blue staining  
  
The gel containing the SDS-Page separated proteins was stained with Coomassie 
Brilliant Blue G 250 staining solution for 20 min. To remove excess dye from the gel 
surface, the gel was incubated in destaining solution overnight. Finally, the gel was 





3.4.7   Western Blot   
  
Proteins bands were transferred from SDS-PAGE to nitrocellulose membrane 0.2 µM. 
The membrane was pre-wetted with transfer buffer for 10 min prior to use. The transfer 
was performed in a Wet-Blotting apparatus (Bio-Rad, München) for 1 h at 400 mA at 
4°C. After transfer, the membrane was incubated in the blocking buffer at 4°C 
overnight. After three washing steps with TBST for 8 min each, the membrane was 
incubated with the primary antibodies anti-tau (TAU-5) in a dilution of 1:1000 in blocking 
buffer for 1h at RT with mild agitation. This was followed with three washing steps with 
TBST. The membrane was then incubated with alkaline phosphatase conjugated 
secondary antibodies (diluted in blocking buffer 1:5000) for 1h at RT and then washed 
three times with TBST.  Antibodies detection was performed using APSubstrate „AP 
Conjugate Substrate Kit “(Bio-Rad) according to manufacturer’s instruction and bands 
were visualised using „GelDocTM XR+ Imaging System“(BioRad, München)  
  
  
3.4.8   Determination of protein concentration  
  
The protein concentration of tau was determined using Pierce 660 nm Protein Assay 
kit. The kit was used according to the manufacturer’s instructions. BSA was used as a 
standard in range of 100 µg/ml to 2 mg/ml. The assay was performed in a 96 well 
microtiter plate. 10   μL of each BSA standard, unknown sample and the blank sample 
were pipetted into the wells. 150 µL of the working reagent were added to each well. 
The plate was incubated under shaking for 5 min at RT. The absorbance was read at 
660 nm. A standard curve based on the absorbance values of the BSA standard was 
generated and the concentration could be determined.  
  
3.5   Phage display for selection of novel binding peptides  
  
The first phage display selection was done against the L-enantiomeric full-length tau 
monomer and the second selection was performed by employing mirror image phage 




3.5.1   Preparation of D-PHF6* fibrils for mirror image phage display selection  
PHF6* stock solution was prepared by dissolving the lyophilized acetylated 
Denantiomeric PHF6* in hexafluoro-2-propanol (HFIP) to a molarity of 1.5 mM.  PHF6* 
fibrillizes spontaneously under incubation at room temperature. The fibrillization was 
started by incubating 100 μM PHF6* in 50 mM NaPi buffer pH 7.0 with 10 μM ThT at 
RT for 30 h. NaPi and 10 μM ThT without addition of peptide was used as a negative 
control. The fibril formation of PHF6* was monitored by ThioflavinT (ThT) assay. For 
ThT fluorescence measurement, 70 μL of the sample were pipetted into a black 96well 
half area µclear flat-bottom plate, three replicates per sample. The fluorescence  
measurement  was  performed  in  photometer  POLARstar  optima  (BMG- 
Labtechnologies, Ortenberg, Germany), excitation/emission wavelengths were set at 
450/482 nm. The mean and the standard deviations of results were calculated using 
Microsoft Excel 2013 (Microsoft Corp.)  
  
3.5.2   The first panning round of the selections  
  
First, 150 µl of either the fibrillized D-enantiomeric PHF6* peptide, prepared as 
described above, or full length tau monomer in concentration of 100 µg/ml (diluted in  
0.1 M NaHCO3; pH 8.5) were immobilized on polystyrene 96-well microtiter plates 
(Greiner Bio-One International GmbH, Frinckenhausen). The plate was covered with 
gas permeable sealing film and incubated at 4°C overnight with 300 rpm agitation. The 
next day, the coating solution was poured off, and the well was blocked with 300 µl 
blocking buffer for 1 h at 4°C and 300 rpm agitation. The blocking solution was 
discarded and the well was washed six times with TBST (TBS + 0.1% [v/v] Tween-20). 
10 µl of Ph.D.-12TM Phage Display Library (equivalent to 1 x 1011 phage) were diluted 
with TBST to 100 µl and pipetted into a coated well. The plate was incubated for 1h at 
RT and 300 rpm. After discarding the unbound phages, the plate was washed 10 times 
with TBST. The bound phages were eluted by decreasing the pH with 200 µl of the 
elution buffer (0.2 M Glycine-HCl (pH 2.2) +1 mg/ml BSA). After 20 min incubation at 
RT with the elution buffer, the bound phages were pipetted into a microcentrifuge tube 





3.5.3   Determination of the output titer  
  
To determine the phage titer following elution, 10 ml LB medium were inoculated with 
one colony of E.coli ER2738 and incubated at 37°C, 130 rpm. When OD600 of 0.5 was 
reached, 10 μl of the eluated phages were taken to prepare 10 to 104- fold serial dilution 
of phage in LB. 100 μl of E. coli ER2738 culture were pipetted into microcentrifuge tubes, 
one for each phage dilution. The infection was then conducted by adding 5 μl of each 
phage dilution to each E.coli culture tube. The tubes were vortexed quickly, and 
incubated at RT for 5 minutes. Subsequently, the infected cells were transferred to 
sterile tubes containing melted Top Agar 45°C, briefly vortexed and immediately poured 
onto pre-warmed LB/IPTG/Xgal plates. The plates were allowed to cool for 5 minutes, 
inverted, and incubated overnight at 37°C. The next day, the plaques on the plates were 
counted and the output titer in plaque forming units (pfu) per ml was calculated.  
  
3.5.4   Amplification of the eluate   
  
For phage amplification, 20 ml of LB-medium containing tetracycline 20 µg/ml were 
inoculated with one colony of E.coli ER2738 and incubated at 37°C and 130 rpm 
shaking. The culture was grown until OD600 reached the early-log phase (0.01–0.05).  
The rest of the eluated phages were amplified by adding the eluate to the 20 ml E.coli 
ER2738 culture and were incubated with shaking for 4.5 hours at 37°C. The culture 
was transferred to a centrifuge tube and centrifuged for 10 minutes at 5000 x g at 4°C. 
The pellet was discarded and the supernatant was transferred to a fresh tube and 
recentrifuged. The upper 80% of the supernatant was transferred to a fresh tube and 
1/6 volume of 20% PEG/2.5 M NaCl was added to it. The phages were precipitated at 
4°C overnight. The next morning, phage precipitation was spun at 5000 x g for 50 
minutes at 4°C, the supernatant was discarded and the pellet was suspended in 1 ml 
of TBS. The suspension was transferred to a microcentrifuge tube and spun at 14000 
rpm for 5 minutes at 4°C.  
The resulting pellet was discarded and the supernatant was pipetted into a fresh 
microcentrifuge tube and reprecipitated by adding 1/6 volume of 20% PEG/2.5 M NaCl 
following by incubation on ice for 60 min. The bacteriophages were pelleted by 




μl of TBS, recentrifuged at 4°C, 14000 rpm for 1 min at the supernatant was pipetted 
in a new tube and stored at 4°C. This was the amplified eluate.  
  
  3.5.5   Determination of the input titer  
  
The amplified eluate was titered, as described in Section 3.5.3 and a serial dilution of 
the amplified eluate 10-1011 was prepared. The dilutions from 108 to 1011 were plated 
on LB/IPTG/Xgal plates, the plates were incubated at 37°C overnight. After counting 
the plaques on the plates, the input titer in plaque forming units (pfu) per ml was 
calculated.  
  
  3.5.6   Biopanning rounds from 2 to 4  
  
The following panning rounds 2-4 were performed as described in Sections 3.5.1-3.5.4. 
For each following panning round the amplified eluate from the previous panning round 
was taken instead of the phage library. After determining the input titer of each round, 
the volume of the amplified eluate which should be taken to the next round was 
calculated to be equivalent to the number of phages used in the first round (1x1011 
phages). Starting from the second panning round, the Tween concentration in the 
washing steps was raised to 0.5% (v/v).  
  
 3.5.7   Enrichment ELISA  
  
To evaluate the success of the selection and to examine the binding properties of the 
selected phages in each panning round to the target, enrichment ELISA was 
performed. 4 wells were coated with the target protein diluted in coating buffer NaHCO3 
at a concentration of 100 µg/ml. As a negative control, a coating buffer without the 
target protein was added to 4 wells.  
The plate was covered with gas permeable sealing film and incubated at 4°C, 300 rpm 
overnight. Next morning, after discarding the coating solution, the wells were 




separate plate, to exclude the plastic binding phages, 80 µl of the amplified eluate of 
each panning round were pipetted into two wells of the 96-well plate, mixed with 80 µl 
of the blocking buffer and incubated on a shaker at RT for 20 minutes. After discarding 
the blocking buffer from the first plate, the plate was washed 6 times with TBST (Tween 
0.1% or 0.5%, the same concentration used in the panning round wash steps). The 
diluted phage eluates were transferred to the corresponding wells followed by 
incubation at RT, 300 rpm for 1h. After washing the plates for six times, 200 µl of HRP-
conjugated anti-M13 antibody (diluted in blocking buffer 1:5000) were added to the 
adequate wells and incubated at RT, 300 rpm for 1h. Subsequently, the plate was 
washed six times and 100 µl of TMB substrate solution were added to each well and 
incubated for 15 minutes at RT with gentle agitation. 100 µl of 20% H2SO4 were then 
added to stop the enzymatic reaction.  When TMB substrate reacts with peroxidase, a 
soluble blue reaction product is obtained and by adding the stop solution the color 
changes from blue to yellow. The absorption was measured at 450 nm with the plate 
reader Multiscan Go (Thermo Fisher Scientific, Darmstadt).  
  
3.5.8   Plaque amplification for ELISA   
  
10 µl of the amplified eluate from the third and fourth panning round were used to 
prepare a serial dilution 10-109. Dilutions from 106-109 were plated on LB/IPTG/Xgal 
plates as described in Section 3.5.3.  
In the next day, for each phage clone to be characterized ,15 ml of LB medium were 
inoculated with a single colony of ER2738 and incubated at 37°C until OD600 0.01– 
0.05. Randomly selected blue plaques from the LB/IPTG/Xgal plates were picked using 
a pipette tip, transferred to the E.coli culture and incubated for 37°C with shaking for 
4.5 hours. The subsequent steps were performed as described in Section 3.5.4 and 
the suspension of each phage clone was stored at 4°C until performing single phage 
ELISA.  
  
3.5.9   Single phage ELISA  
  
Single phage ELISA was performed to test the binding properties of a selected phage 




3.5.7; here instead of the amplified phage eluates from each panning round, the 
purified individual phage clone solutions were applied to the coated plate (Figure 9). 
The rest of the positive phage clones solutions were mixed with an equal volume of 




3.5.10   Extraction of phage DNA  
  
ssDNA of the positive phages that showed a high binding signal to the target in single 
phage ELISA was isolated using QIAprep spin M13 Kit (QIAGEN, Hilden). For each 
phage clone, 10 ml LB+Tet were inoculated with one colony of E. coli ER2738 and 
incubated at 37°C, 130 rpm until OD600 0.01-0.05. Subsequently, 3 ml of the culture 
were infected with 5 µl of phage clone suspension and incubated at 37°C, 130 rpm for 
4.5 h. The isolation of the DNA was conducted according to the instructions of the 
manufacturer „QIAprep® M13 Handbook“(QIAGEN). The DNA was elated in 70 µl 
water.  
The concentration of the ssDNA was measured using Nanodrop Multiscan Go (Thermo 
Fisher Scientific, Darmstadt).  
  
Figure 9: Schematic representation of 
single phage ELISA, which was 
performed to confirm whether a selected 
phage clone binds to the tau protein. The 
plate was coated with tau protein. After 
blocking, each individual phage clone 
solution was added to the respective 
wells and incubated. After washing away, 
the unbound phages, the bound phages 
were detected using antiM13 HRP-
conjugated antibodies. The unbound 
antibodies were washed away and a 
TMB substrate, which reacts with HRP to 
give a blue color, was added. The 
enzymatic reaction was stopped with 
20% H2SO4 and the absorption was 





3.5.11   Sequencing and analysing of phage DNA   
  
The isolated ssDNA samples were sequenced by GATC Biotech AG (Köln), 5 µl of 
ssDNA in concentration ≥ 20 µg/ml were mixed with 5 µl -96 gIII sequencing primer 
(Sigma-Aldrich) in concentration of 10 pmol and sent for sequencing.  
The obtained DNA sequences were translated into amino acid sequences using  
(http://insilico.ehu.es/translate/).  
During rounds of biopanning phages may bind to contaminants in the target sample, 
plastic plates, capturing reagents (streptavidin, biotin) or blocking agent such as BSA. 
In addition, a faster propagation rate of some phage clones can lead to recover such 
clones, regardless of their binding affinity. The obtained peptides that bind to nontarget 
molecules in the selection system and do not have specific affinity to the target protein 
are known as target-unrelated peptides (TUPs) (Menendez and Scott, 2005). Target-
unrelated peptides lead to false positive results. Hence, it is required to determine 
whether the positive clones selected using the phage display library are TUP 
sequences. Therefore, a useful website named SAROTUP, an abbreviation for 
“Scanner And Reporter Of Target-Unrelated Peptides” that assists in the reporting and 
excluding of possible target-unrelated peptides, has been established.   
  
All identified peptides resulting from the selections were compared to already known 
peptides in the SAROTUP database to exclude possible target-unrelated peptides 
obtained via phage display (http://immunet.cn/sarotup/). The hydrophobicity, net 
charge, and molecular weight were determined using the PepCalc  
(https://pepcalc.com/) and Peptide 2.0 Inc (https://www.peptide2.com/).  
  
3.5.12   Single phage ELISA with the same quantity of each phage  
  
After excluding the plastic binders and other target-unrelated phages, another type of 
single phage ELISA was performed by adding the same amount of each phage clone 
to the coated plate.  
10 µl from each phage clone suspension were taken and titered as described in Section 
3.5.3. The next day, the plaques on the plates were counted and the plaque forming 




in Section 3.5.9 with the only modification being that the volume of each phage clone 
suspension that was added to the coated plate, was calculated to contain 3x1010 
phages.  
  
3.5.13   Synthesis of the peptides   
  
All peptides were produced commercially using reversed phase high performance 
liquid chromatography with purity of > 95% (JPT Biotech, Berlin, Germany). In the case 
of FAM-labelled peptides, an additional lysine residue was attached to the respective 
peptide C-terminally. The D- or L-enantiomeric PHF6* and PHF6 peptides were 
obtained N-terminally acetylated. Charge distribution has an important effect on the 
propensity of peptides to form fibrils. By blocking the peptides, which leads to absence 
of N- and C-terminal charges, they will closely mimic the fibrillization of hexapeptides 
fragments (PHF6 and PHF6*) within tau. However, unacetylated PHF6* and PHF6 do 
not fibrillize in vitro.  
  
3.6   In vitro characterization of peptides’ abilities to inhibit the 
aggregation of tau, PHF6* or PHF6 using thioflavin assays  
  
  
3.6.1   Fibrillization of full-length tau protein  
  
Recombinant full-length tau protein does not aggregate alone in vitro in physiological 
conditions (Friedhoff et al., 1998). Therefore, heparin was used as an inducing cofactor 
since heparin-induced tau aggregation represents a good model for pathological 
aggregation of tau. The kinetic of aggregation was measured using THT fluorescence. 
Thioflavin-T (ThT) is a benzothiazole dye which binds to formed ß-sheet structures, 
and the measurement of relative fluorescence intensity leads to quantify the amount of 
bound dye.  
24 µM of tau protein was incubated with 6 µm heparin in HEPES and 10 µM of THT 
was supplemented to solution. Negative controls were tested by incubation of the 
recombinant protein without heparin in the presence of THT and by incubation of 




µclear flat-bottom plate (Greiner Bio-One International GmbH, Frinckenhausen), the 
plate was covered with sealing film and incubated at 37°C for 72 h. Fibril formation was 
quantified by measuring the relative fluorescence intensity at 450/482 nm at a 
POLARstar optima microtiter plate reader (BMG-Labtechnologies, Ortenberg, 
Germany), three replicates per run. The mean and the standard deviations of the 
results were calculated using Microsoft Excel 2013 (Microsoft Corp.).  
  
3.6.2   Full-length tau protein fibrillization inhibition assays  
  
Purified recombinant tau protein at a concentration of 24 μM was incubated with 6 µM 
heparin and 10 µM ThT in an HEPES buffer. The peptides were added in different 
molar ratios 1:10, 1:5 or 1:1 (tau:peptide). As a positive control, tau was incubated with 
heparin and THT. As negative controls, the fluorescence of tau alone with THT was 
measured as well as the fluorescence of the buffer HEPES in the presence of THT. 
The samples were pipetted into a black 96-well µclear flat-bottom plate, the plate was 
covered with sealing film and incubated at 37°C for 72 h. The relative fluorescence 
intensity was measured at 450/482 nm at a POLARstar optima microtiter plate reader. 
The relative fluorescence of the samples with peptides were normalized to the positive 
controls, which were each set to equal 100%. The mean of three absorption values 
was calculated using Microsoft Excel 2013 (Microsoft Corp.), as well as the standard 
deviation.  
  
3.6.3   PHF6* and PHF6 fibrillization inhibition assays  
  
The fibrillization conditions of the hexapeptide segments PHF6 and PHF6* were 
established as previously described in Section 3.5.1, the only difference was using of 
50 µM of PHF6 solution. Also, 100 µM PHF6* or 50 µM PHF6 was incubated with the 
respective peptide at a concentration of 1:10 (PHF6 or PHF6*: peptide) in Napi buffer. 
THT was added to the sample at a concentration of 10 µM. As a positive control, PHF6 
or PHF6* was incubated without peptides in Napi buffer with 10 µM THT. As a negative 
control, Napi buffer was incubated with THT. The samples were pipetted into a 96-well 
black µclear flat-bottom plate, the plate was covered with sealing film and incubated at 




POLARstar optima microtiter plate reader. The mean of three absorption values was 
calculated using Microsoft Excel 2013 (Microsoft Corp.), as well as the standard 
deviation.  
3.7   Characterization of the binding properties of the selected 
peptides to tau monomers, tau fibrils, PHF6* fibrils and PHF6 fibrils 
by ELISA  
  
The plate was coated with tau monomers as well as tau fibrils at a concentration of 10 
µg/ml in NaHCO3 pH 8.3, or with PHF6* fibrils as well as PHF6 fibrils at a concentration 
of 50 µg/ml in NaHCO3. As a negative control, NaHCO3 buffer was incubated in the 
wells in place of the target protein solution. The plate was covered with sealing film and 
incubated at RT with 300 rpm agitation for 1 h. After 3 times of washing with PBST 1% 
Tween-20, the wells were blocked with 1% BSA in PBS for 1h at RT and 300 rpm 
followed by 3 times washing with PBST. The FAM-labeled peptides were added in 
increasing concentrations 1µg/ml, 5 µg/ml, 10 µg/ml and 20 µg/ml, in the case of tau 
monomers and tau fibrils; and 10 µg/ml, 20 µg/ml and 50 µg/ml in the case of PHF6 
fibrils and PHF6* fibrils, then incubated for 1h at RT with 300 rpm agitation. The plate 
was washed 3 times with PBST and a horseradish peroxidase-conjugated sheep anti-
FITC secondary antibody was used to detect bound peptides. Subsequently, the TMB 
substrate solution was transferred to the relevant wells. Finally, the reaction was 
stopped with 20% H2SO4 and the plate was read at 450 nm. The mean of three 
absorption values was calculated using Microsoft Excel 2013 (Microsoft Corp.), as well 













4   Results  
  
4.1   Expression and purification of recombinant tau protein  
  
Purified full-length tau protein was continuously required throughout this project, firstly 
to perform the phage display selection against the tau monomer and subsequently to 
characterize the selected peptides in aggregation assays and to test the binding 
properties of the peptides in ELISA experiments.  
The sequence of the full–length tau gene 2N4R was synthetically cloned into the 
pET28a(+) vector system by Genentech. After the transformation of pET28a(+)-441aa 
plasmid into E.coli BL21 (DE3), protein expression was performed according to 
Margittai et al. (Margittai et al., 2004). Tau protein production was induced with 1 mM 
IPTG and incubated for 3 hours. On SDS-PAGE, the intensity of the tau band in the 
sample post-induction was higher than in the sample pre-induction, indicating that tau 
expression responds to IPTG induction (Figure 10 A). The longest isoform of the 
human protein tau has a molecular weight of 45.8 kDa but migrates at 60 kDa on 
SDSPAGE.  
Tau purification was conducted according to Margittai et al. (2004) with some minor 
modifications; after boiling the cell lysate and precipitating the proteins with ammonium 
sulfate, the suspended cell lysate was purified using a cation exchange column. Tau is 
highly positively charged at neutral pH, with a theoretical PI of 8.24. Therefore, a cation 
exchange chromatography column can separate the tau protein from other 
contaminating proteins. The tau protein bound to the negatively charged matrix and 
was eluted with an increasing salt gradient (Figure 10 B). Subsequently, eluted 
fractions containing tau protein were pooled and passed through an anion exchange 
chromatography column. Here, the target molecule tau passed unbound through the 
positive charged column, while the impurities bound to the column. As shown in figure 
10 C, only a purified tau band was observed on the polyacrylamide gel without any 
additional bands. Most of the tau protein obtained from this method was used for the 
phage display selection against tau monomer.  
The tau protein was also purified according to the protocol reported by KrishnaKumar 




in a one-step purification process through direct boiling. Here, the cell pellet was 
suspended in lysis buffer after 3 hours of induction and directly boiled in a water bath 
for about 10 min. The boiled lysate was purified using one chromatography method, 
cation exchange chromatography. The bound tau was eluted with an increasing salt 
gradient (0.1M-0.7M) and analyzed by SDS-PAGE. The eluted fraction containing 0.3 
M NaCl was taken for further use. In this fraction, a thick tau band and some light bands 
below the tau band were observed on the gel (Figure 11). The tau protein obtained 
from this method was used for the thioflavin T aggregation assays.   
The total obtained amount of tau protein from both protocols was about 3 mg from one 
litre culture.  
 
Figure 10: Example of the expression and purification procedure of full-length tau 





(DE3) cells. The cells were grown until OD600 ≥ 0.6 was reached, a sample was saved (BI= 
before induction), after inducing the cells with a final concentration of 1 mM IPTG for 3 hours 
(AI= after induction), the cells were pelleted by centrifugation. The supernatant was discarded 
and the cells pellet was suspended in lysis buffer and boiled. The lysate was centrifuged again 
and the supernatant containing tau proteins was saved (Sup. = supernatant). (B) After 
precipitating the proteins with ammonium sulfate, the suspended cell lysate was loaded into a 
cation exchange column. After collecting the flow through (FT=flow through), the column was 
washed with HEPES buffer (W= solution collected after washing step) and tau protein was 
eluted with an increasing salt gradient (0.1M -0.7M NaCl) (0.1M-0.7M=eluted fractions with 
NaCl concentration from 0.1-0.7M). (C) Fractions containing tau protein were collected (Before 
AIEX= eluted fractions containing tau before loading into anion exchange column) and the flow 
through which contains purified tau was collected (FT after AIEX= flow through after loading 
into anion exchange column). Samples were taken after each step and prepared for SDS-gel, 
10 µl were loaded into SDS-gel as well as 5 µl from the molecular weight marker, kDa 




Figure 11: Example of the expression and purification procedure of full-length tau 
according to KrishnaKumar et al., 2017. The human protein tau was expressed in E. coli BL21 
(DE3) cells. The cells were grown until OD600 ≥ 0.6 was reached, a sample was saved (BI= 
before induction), after inducing the cells with a final concentration of 1 mM IPTG  for 3 hours 
(AI= after induction), the cells were pelleted by centrifugation. The supernatant was discarded 
and the cells pellet was suspended in lysis buffer and boiled. The lysate was centrifuged again 
and the supernatant containing tau proteins was saved (Sup. = supernatant). The supernatant 
was loaded into a cation exchange column. After collecting the flow through (FT=flow through), 
the column was washed with an HEPES buffer (W= solution collected after washing step) and 
tau protein was eluted with an increasing salt gradient (0.1M -0.7M NaCl) (0.1M-0.7M=eluted 
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prepared for SDS-gel, 10 µl were loaded into SDS-gel as well as 5 µl from the molecular weight 
marker, kDa (Precision Plus ProteinTM Standard Dual, Bio-Rad).  
 
Western blot analysis of the purified tau protein   
  
Western blot was performed to determine the nature of additional bands under the 
band of tau protein after performing the purification according to KrishnaKumar et al., 
2017. Samples were taken from the eluted fractions containing 0.2 and 0.3 M NaCl. 
After separating the proteins using SDS-PAGE, the protein bands were transferred into 
a membrane and the bands were visualized after immunodetection. We expected the 
bands below the main band of tau protein to be degradation products, which potentially 
present additional bands. Using a tau specific antibody, we were able to confirm that 
these bands were degradation products, which would migrate ahead of the band of 
interest a cause to their lower molecular weight.  
The signal demonstrated that the protein running at a size of around 60 kDa is the 
recombinant protein tau, which has a theoretical molecular weight of 45.8 kDa. 
However, the Western Blot showed that all fragments react with the tau specific 
antibody anti-TAU 5, indicating that all fragments belong to the recombinant protein 
tau. In a 0.3 M fraction, a light band above tau protein by 250 kDa could be seen. This 
band was interpreted as tau dimers or trimers (see Figure 12).   
 
Figure 12: Western blot analysis of purified recombinant tau protein. After cation exchange 
chromatography, samples from the eluted fractions consisting of 0.2 M NaCl and 0.3 M NaCl 
were taken and prepared for SDS-PAGE. After separating proteins by electrophoresis, the 
separated proteins were transferred from the gel onto a nitrocellulose membrane. Subsequently, 
the membrane was blocked. After blocking, primary antibodies anti
 




membrane and incubated.  After washing, the secondary antibodies (goat-anti-mouse AP 
conjugate) were added onto the membrane. Antibodies were detected using AP substrate „AP 
Conjugate Substrate Kit “and bands were visualised using „GelDocTM XR+ Imaging 
System”.kDa: molecular weight marker, 0.2 M: eluted fraction containing 0.2 M 
 
NaCl, 0.3 M: 
eluted fraction containing 0.3 M NaCl  
 
4.2   Phage display selection against full-length tau monomer  
  
The principal aim of this Ph.D. project was to select D-enantiomeric peptides that bind 
to the tau protein and inhibit its pathological aggregation. Usually, to generate D-
enantiomeric binding peptides to a specific target, mirror image phage display selection 
against the D-enantiomeric form of the target is performed. Since it was difficult to 
obtain D-enantiomeric full-length tau protein (length 441amino acids) for mirror image 
phage display from manufacturers of peptides, the L-enantiomeric full-length tau 
monomer was used as a target for the selection. The obtained L-enantiomeric peptides 
were then synthesized as D-enantiomeric peptides.  
  
To obtain tau specific binding partners, 1x 1011 phages from Ph.D.-12 Phage Display 
Peptide Library were added to a tau coated plate, the unbound phages were washed 
away and the bound phages were eluted by decreasing the pH. The eluted phages 
were amplified in E.coli ER2738 and taken for another panning round. Four panning 
rounds were performed, after each panning round the input titer and the output titer 
were calculated. The number of plaque forming units (pfu) was counted and phages 
were prepared to the next panning round by diluting to a concentration of 1x 1011 
phages.  
    
4.2.1   Enrichment ELISA after four panning rounds  
  
An enrichment ELISA was carried out to evaluate in which panning round the entire 
phage pool had the highest affinity to the tau. The wells were coated with tau protein 
and the amplified phage pools from all panning rounds were added to coated wells. 
The bound phages were detected with anti-M13 HRP conjugated antibodies. The 
obtained signal intensity was proportional to the amount of bound HPR conjugated 
antibody and thus proportional to the amount of binding phages in the respective 
eluate. As negative controls, wells were filled with coating buffer and coating buffer 




The absorbance signal of wells containing tau, representing the binding, was 
significantly higher than that of negative control wells. This indicated the success of the 
selection (Figure 13). 
 
As expected, the increase in the ELISA signal following the second round of biopanning 
is likely due to the presence of a greater abundance of target-binding phages in the 
third and fourth round pool. The enrichment ELISA can be estimated after rounds of 
selection by calculating the ratio of specific binding signal versus non-specific binding 
signal. Each ratio value is obtained using the absorbance of the target wells to the 
negative control wells. The binding ratio in this selection was more than 2 for all panning 
rounds (Table 8). A ratio threshold of 2 or greater indicates the likely presence of 
specific binding phages (Miersch et al., 2015). 
 
To isolate single phage clones, the eluate of the later rounds of selection (i.e. rounds  
3 and 4, which showed higher binding signal to the target), was infected into E.coli 
ER2738 and plated on IPTG/Xgal LB plates. The binding properties of the individual 
phage clones to the target were tested using single phage ELISA.  
    
 
Figure 13: Enrichment ELISA showed the enrichment of tau specific phages during the 
affinity selection process. Wells were coated with 100 µg/ml tau protein, wells containing 
only buffer or buffer with 1% BSA were used as negative controls. After blocking, amplified 
phages from round one to four were added to the respective wells and incubated for 1h. The 
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HRP monoclonal antibody. After washing the unbound antibodies, the enzymatic 
transformation of the TMB substrate was measured at 450 nm. 
 
Table 8: Binding ratio of tau monomer to the negative control (buffer) by enrichment 
ELISA.  
Round of panning  1  2  3  4  
Enrichment ELISA (A450 nm ratio) tau 
monomer: buffer  
4.8  10  20.2  35.5  
 
  
4.2.2   Single phage ELISA   
  
Individual phage clones from the third and fourth panning rounds were picked from 
LB/IPTG/Xgal plates, amplified in E.coli ER2738 and, after several steps of 
precipitation and centrifugation, individual phage stocks were produced. The resulting 
phage stocks were added to tau coated wells to determine whether a selected phage 
clone binds to the target, without using a target-specific antibody. The detection was 
performed using anti-M13 HRP conjugated antibodies.  
Single phage ELISA data was analyzed by comparing the absorbance of the wells 
coated with tau protein to the absorbance of the negative control wells.  As shown in 
Figure 14, some phage clones showed a significantly higher absorption value in 
comparison to the negative controls, indicating binding to tau protein. These clones 
included clone numbers, e. g. 2, 3, 5 and 7. Other clones exhibited slightly stronger 
binding to their antigen compared to negative controls, e.g. clones 22, 26 and 27. 
Phages such 9, 21 and 31 exhibited a relatively high binding to the negative control 
wells, potentially indicating a plastic binder phage.  
The DNA of the positive clones, with the potentially highest binding to tau protein, was 
sequenced to determine the identity of the peptide expressed on the phage surface.  
The binding properties of 96 clones from the third and fourth panning round were 







Figure 14:  Identification of binding properties of individual randomly-selected phage 
clones to tau protein with single clone ELISA. Tau protein in concentration of 100 µg/ml 
was immobilized on the plate. As negative controls, wells were filled with the coating buffer. 
After blocking, individual phage stocks were added to the respective wells and incubated for 
1h. After 6 times of washing, phages were detected with anti-M13 HRP monoclonal antibody. 
After washing the unbound antibodies, the enzymatic transformation of the TMB substrate was 
measured at 450 nm. The figure represents an example of 32 phage clones, approximately 96 
phage clones were tested. Later, the synthesized peptides from the phage clones 4, 5, 17, 20, 
23, 24, 25 and 29 were named as MM1, MM2, MM3, MM4, MM5, MM6, MM7 and MM8 
respectively.  
  
4.2.3   DNA extraction for identification of peptides sequences   
  
The peptide sequences expressed by the promising phages were identified by DNA 
sequencing of the corresponding genome. Some phage clones did not contain an 
insert, which was designed to add a peptide spacer between the peptide sequence and 
the DNA of the phage.   
All peptide sequenced after the selection are listed in Table 9. Different characteristics 
of the identified peptides, such as the charge, hydrophobicity and molecular weight, 
were analyzed using web tools like PepCalc (https://pepcalc.com/) and Peptide 2.0 Inc 
(https://www.peptide2.com/) listed in Table 9.  
Interestingly, we did not find any dominating amino acid sequences in 28 sequences. 




were compared to those sequences listed in the SAROTUP database (“Scanner And 
Reporter Of Target-Unrelated Peptides", a website which can detect target-unrelated 
peptides resulting from biopanning: http://immunet.cn/sarotup/), and the PepBank 
database  (database  of  peptides  from  public  data  sources: 
http://pepbank.mgh.harvard.edu/). However, no hits were found.  
From the identified 28 sequences, a phage clone (No. 9, KVWPSPSMMFST) was 
predicted in SAROTUP as a plastic binder. Phage clones that according to SAROTUP 
had a relatively high probability of being rapidly growing phages were also excluded 
(i.e. YSLRLTSVTAPT, TLGTFTHNKPPH, and NHTEASSPLNRA).  
Some phage clones were recognized to be rapidly growing phages with low probability. 
The faster growing rate of some phage clones renders such clones predominant and 
more likely to be isolated despite they are unlikely to specifically bind to the target. To 
exclude faster propagation of certain phage clones, the remaining peptide sequences 
were additional screened for their binding to tau monomer by ELISA using the same 
concentration of phages from each individual phage stock.  
Table 9: selected peptides from the phage display selection against the tau monomer. 
The peptides’ sequences were determined after DNA sequencing of the promising phage 
clones. The frequency of each sequence was listed in the table. Peptides’ characteristics like 
charge, hydrophobicity and molecular weight in Dalton were also analyzed using the websites 
Peptide 2.0 Inc and PepCalc and listed below. Each sequence was allocated a number in the 
list.  
No.  sequence  frequency  charge  hydrophobicity  MW (Da)  name  
1   HLSSPYWIGSMR  4/28  +1  41%  1433. 64   MM7  
2   HNTGGKMDLPKW  1/28  +1.1  33%  1383.58  _  
3   TSAVWSKTVSLS  1/28  +1  41%  1265.41      _  
4   DPLKARHTSVWY  1/28  +1  41%  1472.65  MM3  
5   YSLRLTSVTAPT  3/28  +1  41%  1308.48  _  
6  NHTEASSPLNRA  1/28  +0.1  33%  1296.35      _  
7   SSMALDQYTQGS  1/28  -1  25%  1287.36  _  
8   DTLVKQNKLMAA  1/28  +1  50%  1331.58  MM6  
9   KVWPSPSMMFST  1/28  +1  58%  1397.66  _  
10   HLTATELANSYH  1/28  -0.8  33%  1356.44  MM8  




12   HMSYGNGTRDTP  2/28  +0.1  16%  1335.41  MM4  
13   SYPHSTSKDLKP  1/28  +1.1  25%  1359.48  _  
14   TLGTFTHNKPPH  1/28  +1.2  33%  1349.49  _  
15  SPHLHTSSPWER  1/28  +0.2  33%  1433.53  _  
16  GSPLSNPTRMWL  1/28  +1  50%  1358.57  MM5  
17   TSHHLHNTTTRG  1/28  +1.3  8%  1361.42  _  
18   NLPYPPTLLYAS  1/28  0  58%  1348.54  _  
19   DIYAHPKSASHR  1/28  +1.2  33%  1381.5  _  
20   YLNTAWGNIMPV  1/28  0  58%  1378.6  _  
21  NHTEASSPLNRA  1/28  +0.1  33%  1296.35  _  
21   HSLRSSHHPTPG  1/28  +1.6  25%  1312.40  _  
22   GSWNTFRAQPTI  1/28  +1  41%  1377.5  MM1  
  
4.2.4   Single phage ELISA using the same concentration of each phage clone  
  
After using SAROTUP to exclude known target-unrelated peptides, 18 peptides 
remained. Before determining which peptides should be synthesized and further 
characterized, false positive results had to be distinguished from true positive clones. 
The binding properties of the remaining phage clones to tau monomer were tested 
again by ELISA using the same concentration of each phage clone. After amplifying 
each phage clone stock in E.coli and titering the obtained phage solution, the plaques 
on LB/IPTG/Xgal plates were counted and the pfu/ml was calculated. The same phage 
concentration: 3× 1010 pfu/ml from each phage solution was added to the tau-coated 
plate and the bound phages were detected using anti-M13 HRP monoclonal antibody. 
After measuring the plate, the absorption values of the tau-coated wells in the cases of 
phage clones number 1, 4, 8, 10, 11, 12, 16 and 22 were relatively high in comparison 
to the negative controls wells (buffer and buffer containing 1% BSA). This indicated a 
binding of these phage clones to the tau protein. Phage clone No.22 resulted in the 
highest absorption signal (Figure 15)  
Eight  peptides  (No.1  HLSSPYWIGSMR,  No.4  DPLKARHTSVWY,  No.8 
DTLVKQNKLMAA, No.10 HLTATELANSYH, No.11 LTPHKHHKHLHA, No.12 




selected to be synthesized as L-enantiomer peptides to further characterize them and test 
their potential to inhibit tau aggregation.   
  
 
Figure 15:  After sequencing, identification of the binding properties of predicted 
positive phage clones to the tau protein by single clone ELISA using the same 
concentration of each phage clone.  100 µg/ml of tau protein was immobilized on the plate. 
For negative controls, coating buffer and coating buffer containing 1% BSA were used. After 
blocking, individual phage stock in concentration of 3x1010 were added to the respective wells 
and incubated for 1h. After 6 times of washing, phages were detected with anti-M13 HRP 
monoclonal antibody. After washing the unbound antibodies, the enzymatic transformation of 
the TMB substrate was measured at 450 nm. The synthesized peptides from the phage clones 
22, 11, 4, 12, 16, 8, 1 and 10 were named as MM1, MM2, MM3, MM4, MM5, MM6, MM7 and 
MM8 respectively.  
  
 
4.3   In vitro characterization of peptides abilities to inhibit the 
aggregation of full-length tau using thioflavin assays  
  
4.3.1   Aggregation of tau protein  
  
Before beginning to test the ability of the selected peptides to inhibit the aggregation of 
full-length tau, it was necessary to establish the fibrillization conditions of the tau 
protein.  
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To induce the aggregation of tau, the polyaninon heparin was added to tau. Thioflavin 
T, a fluorescence dye which binds to protein fibrils, was added to the solution. The 
fluorescence changes were monitored after transferring the solutions to a black plate 
and the relative fluorescence was measured every hour for 72h. As negative controls, 
tau was incubated in HEPES buffer with ThT, without the addition of heparin, as well 
as HEPES buffer was incubated with THT. By starting with the measurement 0 h, it 
was possible to detect a very low fluorescence signal as there were no fibrils in solution 
and most dyes did not bind to the intermediates formed. A considerable increase in the 
fluorescence signal of THT was observed in the first 12 hours and it continued to 
increase until 36 h. This increase in fluorescence occurred as the dye (THT) was able 
to bind to the tau fibrils formed in this phase. After 36 hours of incubation, a plateau of 
the signal was reached, due to the saturation of the fibrils present. Both negative 
controls were constant at a low relative fluorescence intensity (see Figure 16).   
 
Figure 16: An increase in THT fluorescence intensity indicates tau protein aggregation 
in the presence of heparin, whereas tau protein does not aggregate in the absence of 
heparin. 24 μM recombinant full-length tau protein, 6 μM heparin and 10 μM ThT were 
incubated in HEPES buffer (black line). As a negative control, 24 μM tau was incubated in 
HEPES with 10 µM ThT, without addition of heparin (blue line) as well as HEPES buffer was 
incubated with 10 µM ThT (red line). All solutions were pipetted into a black 96-well µclear 
flatbottom plate and incubated at 37°C for 72 h in photometer POLARstar optima. The relative 
fluorescence intensity was read out at excitation and emission maxima of 450 and 482 nm, 
respectively, at a POLARstar Optima microtiter plate reader (mean +/- standard deviations of 
results, three replicates per run).  
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4.3.2   The potential of the selected L-enantiomer peptides to inhibit the 
aggregation of full-length tau  
  
To test the ability of the L-synthesized peptides to inhibit the aggregation of tau in vitro, 
thioflavin assays were performed. The peptides were added to the aggregation mixture 
at a molar ratio of 1:5 and/or 1:10 (tau:peptide), respectively. As a positive control, tau 
was incubated with heparin without the addition of peptides, negative controls were tau 
alone with THT and buffer including THT. The relative fluorescence of the positive 
control was set to be 100% after 72 h of incubation and the relative fluorescence of the 
samples was normalized to the positive control. As shown in Figure 17, MM2 and MM3 
significantly reduced tau aggregation, especially in a ratio of 1:10. MM2 reduced the 
fibril formation of tau to approximately one half in a molar ratio of 1:5 and in molar ratio 
of 1:10 MM2 accomplished almost complete inhibition of tau fibril formation.  In the 
case of MM3, both molar ratios 1:5 and 1:10 were almost equally efficient in 
significantly inhibition of tau fibril formation. MM4 and MM5 exhibited no significant 
effect on tau fibril formation, while peptides MM1, MM6, MM7 and MM8 appeared to 





















Figure 17: ThT assays indicate the ability of MM2 and MM3 to inhibit or reduce fibril 
formation of tau whereas MM1, MM4, MM5, MM6, MM7 and MM8 do not act as tau 
aggregation inhibitors. (A) Peptides MM2 and MM3 in molar ration 1:5 and 1:10 (tau:peptide) 
(B) peptides MM1, MM4, MM5, MM6, MM7 and MM8 in molar ratio 1:10 (tau:peptide).  24 µM 
tau and 6 µM heparin were incubated with and without the peptides in a molar ratio of 1:5 
and/or 1:10 (tau:peptide), respectively. Upon addition of 10 µM ThT, 70 μL sample volume 
were pipetted into each well of a black 96-well µclear flat-bottom plate and incubated at 37°C 
for 72 h in photometer POLARstar Optima. The relative fluorescence intensity was read out at 
excitation and emission maxima of 450 and 482 nm, respectively (mean +/- standard 
deviations of results, three replicates per run). The relative fluorescence for the positive control 
(tau and heparin without peptides) after reaching the saturation level (36 hours of incubation) 
was set at 100%.  
  
D-enantiomeric peptides are extremely protease stable and their suitability for in vivo 
applications has been demonstrated; consequently, the promising peptides MM2 and 
MM3 were ordered as D-enantiomer peptides and D-retro-inverso peptides to further 
investigate their ability to inhibit tau fibril formation. In addition, the promising peptides 
were obtained as FAM-labeled versions to assess their binding to tau monomers and 
tau fibrils. The newly synthesized peptides are listed in Table 10.  
Table 10: MM2 and MM3 were selected for further characterization. The respective Dpeptide 
as well as the retro-inverso version were synthesized by JPT Peptide Technologies GmbH. The 
names and the sequences of newly synthesized peptides are listed below. 
 peptide name   sequence  




MMD2rev  d-ahlhkhhkhptl  
MMD3  d-dplkarhtsvwy  
MMD3rev  d-ywvsthraklpd  
MMD2-Lys(FAM)-NH2  d-ltphkhhkhlha-lys(FAM)-NH2  
MMD3-Lys(FAM)-NH2  d-dplkarhtsvwy-lys(FAM)-NH2  
   
4.3.3   The potential of the selected D-enantiomer peptides to inhibit the 
aggregation of full-length tau  
  
To investigate the potential of the selected D-peptides MMD2, MMD2rev, MMD3 and 
MMD3rev to inhibit fibrillization of full-length tau, thioflavin fluorescence assays were 
performed. Tau aggregation was initiated by the addition of heparin to the tau protein 
at a concentration of 24 μM, the mixtures were incubated in the presence or absence 
of the respective peptide in a molar ratio of 1:10. After 36 hours of incubation, the 
positive control sample (tau with heparin) reached a saturation level, and the 
fluorescence intensity value was set to 100%. As can be seen in Figure 18, neither 
MMD2 nor MMD2rev inhibited the aggregation of tau significantly at molar ratio of 1:10 
(tau:peptide). MMD2 reduced the aggregation of tau to about 90% and MMD2rev 
reduced the aggregation to approximately 70%. However, both peptides MMD3 and 
MMD3rev significantly inhibited formation of tau aggregates at a molar ratio of 1:10. 
MMD3 and MMD3rev proved to be equally efficient in significantly inhibiting the 
formation of tau fibrils.  
Furthermore, the binding properties of MMD2 and MMD3 to tau monomers as well as 
to tau fibrils were investigated using ELISA. To enable the use of this method, FAM 
labeled versions of the peptides were ordered as displayed in Table 10. The retro 
inverso form of the D-peptides exhibits usually a very similar pattern of binding 
comparing with their D-peptides, therefore the binding properties of MMD2rev and 






Figure 18: The ability of the selected peptides MMD2, MMD2rev, MMD3 and MMD3rev to 
reduce or inhibit formation of tau fibrils. 24 µM tau and 6 µM heparin were incubated with 
and without the peptides in a molar ratio of 1:10 (tau:peptide), respectively. Upon addition of 
10 µM ThT, 70 μL sample volume were pipetted into each well of a black 96-well µclear 
flatbottom plate and incubated at 37°C for 72h in photometer POLARstar Optima. The relative 
fluorescence intensity was read out at excitation and emission maxima of 450 and 482 nm, 
respectively (mean +/- standard deviations of results, three replicates per run). The relative 
fluorescence for the positive control (tau and heparin without peptides) after reaching 
saturation level (36 hours of incubation) was set at 100%.  
  
4.4   Demonstrating the binding properties of the selected peptides 
to tau monomers as well as to tau fibrils using ELISA  
  
The binding properties of MMD2 and MMD3 to tau monomers and tau fibrils were 
tested using ELISA. After coating a 96-well plate with 10 µg/ml tau monomers as well 
as tau fibrils, the FAM-labeled peptides MMD2-FAM and MMD3-FAM were added in 
increasing concentrations. The detection was performed with anti-FAM HRP antibodies 
and absorbance was measured at 450 nm. As a negative control, coating buffer only 
was incubated in the wells.  
The binding of MMD2 and MMD3 to tau monomers and tau fibrils could be 
demonstrated. Both peptides did not show any significant difference in their binding to 












monomers. The binding of MMD2 to tau monomers and tau fibrils appeared to be 
generally stronger than MMD3 (Figure 19).  
  
 
Figure 19: ELISA to demonstrate the binding properties of peptide MMD2 and MMD3 to 
tau monomers and tau fibrils. To enable the use of this method, a FAM-labeled version of 
the peptides was synthesized. The plate was coated with tau monomers and fibrils in a 10 
μg/mL concentration. As a negative control, a NaHCO3 buffer was incubated in the wells in 
place of the tau protein solution. After blocking with 1% BSA in PBS, the peptides MMD2-FAM 
and MMD3-FAM were added in increasing concentrations (1µg/ml, 5 µg/ml, 10 µg/ml and 20 
µg/ml), a horseradish peroxidase-conjugated sheep anti-FITC secondary antibody was used 
to detect the bound peptide. Subsequently, the TMB substrate solution was transferred to the 
relevant wells. Finally, the reaction was stopped with 20% H2SO4 and the plate was read at 
450 nm. The absorption values were presented after subtraction of the negative controls. The 
mean of three absorption values (at 450 nm) is shown, as well as the standard deviation.   
   
4.5   Mirror image phage display selection against D-PHF6* fibrils  
  
In order to select more D-peptide inhibitors of tau aggregation, a second phage display 
selection was done using fibrils of the D-enantiomeric PHF6* as a target. The 
hexapeptide segment PHF6*, which represents residues 275 to 280 of the tau protein, 
was chosen as a target in our second selection as Seidler et al., 2018 reported that 
this segment has a powerful role in tau aggregation. We used the D-amino acid 
configuration of the target PHF6* in order to employ mirror phage display, an elegant 
and direct way to obtain peptide ligands in the D-conformation. In principle, the 
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selection was carried out exactly as in phage display but against the mirror image of 
the original target molecule.   
  
4.5.1   Preparation of D-PHF6* fibrils for mirror image phage display selection  
  
D-enantiomeric PHF6* fibrils were prepared for the selection, D-PHF6* was incubated 
in sodium phosphate buffer (Napi) in the presence of THT for at least 30 hours. 
Aggregation was detected by measuring ThT-fluorescence. The fibrillization was 
started after the incubation at 0 h. After 6 hours of incubation, PHF6* exhibited a greater 
rate of aggregation and the self-assembly into fibrils continued until 28 h. After 28 
hours of incubation, a plateau or the saturation point was attained. In contrast, the 
relative fluorescence intensity of the negative control was stable at a low value. The 
resulting fibrils were then immobilized in a microtiter plate and used as a target for 
mirror image phage display (Figure 20).  
  
 
Figure 20: PHF6* fibrillizes spontaneously by incubation at room temperature. The assay 
was carried out using 100 μM PHF6* in NaPi buffer with 10 μM ThT (black line). As negative 
control, a solution containing 10 μM ThT in NaPi (without PHF6*) was used (brown line). 
Solutions were pipetted into a black 96-well half area µclear flat-bottom plate and incubated at 
RT for 30 hours. The relative fluorescence intensity was measured at excitation and emission 
maxima of 450 and 482 nm, respectively (mean +/- standard deviations of results, three 
replicates per run).  
  
















After immobilization of D-PHF6* fibrils onto a microtiter plate, 1x 1011 phages from 
Ph.D.-12 Phage Display Peptide Library were added, the unbound phages were 
washed away and the bound phages were eluted. The eluted phages were amplified 
in E.coli and taken for another panning round. Four panning rounds were performed, 
after each panning round the input titer and the output titer were calculated. After 
counting the number of plaque forming units (pfu), the phages were diluted to a 
concentration of 1x 1011 phages and used for the subsequent panning round. The 
binding properties of the four eluted phages pools from each panning round were 
screened using enrichment ELISA. The four eluates were added to PHF6* coated 
wells. For non-specific binding, negative control wells were filled with coating buffer or 
coating buffer including 1% BSA.  
As Figure 21 shows, the absorption value of the negative control wells in all panning 
rounds (which represent the binding) was relatively low in comparison to the absorption 
value of the wells coated with PHF6* fibrils. These results indicating specific binding of 
each eluted phage from different rounds of biopanning. We were unable to observe 
any increase in the absorption signal with increasing numbers of panning, which was 
unexpected. However, the first and second round of biopanning exhibited highest 
signal in the polyclonal phage ELISA. The binding ratio for all panning rounds was more 
than 2 (Table 11). 
 
The binding properties of the individual phage clones from the third and fourth panning 






























Figure 21: Enrichment ELISA showed a binding of the four panning rounds eluates to 
PHF6* fibrils. Wells were coated with 100 µg/ml D-PHF6* fibrils, wells containing only buffer 
or buffer with 1% BSA were used as negative controls. After blocking, amplified phages from 
rounds one to four were added to the respective wells and incubated for 1h. After washing, 
bound phages were detected with anti-M13 HRP monoclonal antibody. The unbound 
antibodies were washed away, the TMB substrate was added and the reaction was stopped 
with 20 %H2SO4. Finally, the absorption was measured at 450 nm.  
 
 
Table 11: Binding ratio of D-PHF6* fibrils to the negative control (buffer) by enrichment 
ELISA  
Round of panning  1  2  3  4  
Enrichment ELISA (A450 nm ratio) tau 
monomer: buffer  
10.3  15.8  7.4  6.8  
 
  
4.5.3   Single phage ELISA  
  
The eluates of the third and fourth panning rounds were plated on LB/IPTG/Xgal plates. 
Individual phage stock solutions were prepared by picking individual clones from 
LB/IPTG/Xgal plates and amplifying them in E.coli. After several steps of precipitation 
and centrifugation, individual phage stocks were produced and added to PHF6* fibrils 
coated wells to determine whether a selected phage clone would bind to the target.  
Most of the phage clones exhibited a significantly high absorption value in comparison 
to the negative controls, indicating a binding to PHF6* fibrils. This included clone 
numbers (e. g. 1, 2, 3, 4, 6, 19 and 26). Other clones exhibited a relatively low binding 
to PHF6* fibrils in comparison, including phage numbers 13, 15, 17, 20, 23 and 28. 
Phages like No. 5, 7 and 8 exhibited an extremely low binding to PHF6* fibrils coated 
wells, potentially indicating a phage clones with nonspecific binding (Figure 22).  
The DNA of the promising phage clones was extracted and sequenced to identify the 
sequences of the peptides displayed on the surface of phages. Over 60 clones were 
screened for specific binding to the immobilized PHF6* fibrils. Figure 22 represents an 






Figure 22: Identification of binding properties of individual randomly-selected phage 
clones to PHF6* fibrils by single clone ELISA. 100 µg/ml PHF6* fibrils were immobilized on 
the plate. As negative controls, wells were filled with the coating buffer. After blocking, 
individual phage stocks were added to the respective wells. After washing, bound phages were 
detected with anti-M13 HRP monoclonal antibody. Subsequently, the TMB substrate solution 
was transferred to the relevant wells. Finally, the reaction was stopped with 20% H2SO4 and 
the plate was read at 450 nm. The figure represents an example of 28 phage clones, 
approximately 60 phage clones were tested. Later, the synthesized peptides from the phage 
clones 2, 3, 10,11,14, 24 and 26 were named as MMP1, MMP2, MMP3, MM3, MMP4, MMP5 
and MMP6 respectively.  
  
4.5.4   DNA extraction for identification of peptides sequences  
   
The DNA of the promising phage clones was extracted and sent for sequencing. The 
obtained DNA sequences were then translated into amino acid sequences. In total, 31 
displayed peptides were identified and no one single dominating peptide sequence was 
evident in 31 sequences. The peptide sequences from the selection against PHF6* 
fibrils are listed in Table 12. Interestingly, the sequence of peptide MM3, which was 
obtained in the first selection against full-length tau and acted as a tau aggregation 
inhibitor, was also obtained in the selection against PHF6* fibrils.  
Different characteristics of the peptides such as charge, hydrophobicity and molecular 
weight were analyzed using web tools like PepCalc (https://pepcalc.com/) and Peptide 
2.0 Inc (https://www.peptide2.com/).  
MMP1 





0 , 0 
0 , 5 
, 0 1 
1 , 5 
2 , 0 
2 , 5 
3 , 0 
5 3 , 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
phage clone number 




To exclude target-unrelated peptides from biopanning results, the peptide sequences 
were screened using the SAROTUP database (“Scanner And Reporter Of Target 
Unrelated  Peptides".  SAROTUP  predicted  one  phage  clone (No. 28, 
DHMPPYHWRPWD) to be a plastic binder and some phage clones were predicted to 
be rapidly growing phages (No. 3, 7, 14, 15, 19, 20, 25, 27 and 29) (Table 12). After 
excluding possible target-unrelated peptides, six peptides MMP1, MMP2, MMP3, 
MMP4, MMP5 and MMP6 were selected for further characterization. The peptides were 
synthesized as L-enantiomeric peptides to test their ability to inhibit the aggregation of 
PHF6*. Usually, the peptides obtained after mirror image phage display are synthesized 
directly as D-peptides and tested against the L-enantiomeric form of the target. However, 
due to the high cost of synthesizing six D-enantiomeric peptides, we decided to order 
them first in the L-enantiomeric form and test them against DPHF6* using THT assay. 
Subsequently, the promising L-peptides were synthesized as D-peptides.  
Table 12: Selected peptides from mirror image phage display selection against D-PHF6* 
fibrils. The peptides’ sequences were determined after DNA sequencing of the positive phage 
clones. The frequency of each sequence was listed in the table. Peptides’ characteristics like 
charge, hydrophobicity and molecular weight in Dalton were also analyzed using the websites  
Peptide 2.0 Inc and PepCalc and listed below. Each sequence was given a number in the list.  
No.  sequence   frequency  charge  hydrophobicity  MW  
(Da)  
Name  
1  YPVRAVPNQSGQ  1/31  +1  41.67%  1315.43  _  
2  YVTHYNANYSNL  2/31  +0.1  25%  1458.53  _  
3  YSLRLTSVTAPT  1/31  +1  41%  1308.48     
4  DPLKARHTSVWY  1/31  +1  41%  1472.65  MM3  
5  MPHLHPSSANWS  1/31  +0.2  50%  1363.5  _  
6  GRDMPMSALMRH  1/31  +1.1  50%  1401.69  MMP1  
7  NHNHGYPITHRT  1/31  +1.3  16.67%  1446.53  _  
8  GIALSEPVPNHH  1/31  -0.8  50%  
 
1270.39    _  
9  WPHDTKRYLFPA  1/31  +1.1  50%  1530.73  MMP2  
10  YPMHPGYGTKLG  1/31  +1.1  33.33%  1320.52  _  
11  YSGVSRGHSHGP  1/31  +1.2  16.67%  
 
1240.29    _  
12  YVPANNYHLHSP  1/31  +0.2  41.67%  1411.52  MMP3  
13  SLSPIFIQNGTN  1/31  0  41.67%  1290.42  _  




15  SDASMQNKLPLW  1/31  +0.1  50%  1418.6  _  
16  NLWKGLDGSGRT  1/31  +1  25%  1303.42  _  
17  HSDLWRRSFELM  1/31  +0.1  25%  
 
1576.78    MMP6  
18  TPSYLMPLAPHT  1/31  +0.1  58.33%  1327.55  _  
19  SLLHPNAIMPRT  1/31  +1.1  58.33%  1349.6  _  
20  DEDQQVHYQIWR  1/31  -1.9  25%  1616.69  _  
21  HPAPHRYHSNLH  2/31  +1.4  33.33%  1465.58  MMP4  
22  TRTATLADNSWL  1/31  0  33.33%  1348.46  MMP5  
23  HLTATELANSYH  1/31  -0.8  33.33%  1356.44  _  
24  MKAHHSQLYPRH  1/31  +2.3  33.33%  
 
1504.72    _  
25  SYPSNALSLHKY  1/31  +1.1  33.33%  
 
1379.52    _  
26  NHSDKQMSSAFL  1/31  +0.1  33.33%  1364.49  _  
27  SLSPAGYTRLSL  1/31  +1  41.67%  1264.43  _  
28  DHMPPYHWRPWD  1/31  -0.8  50%  1636.79  _  
29  KIHHSLTIRTAA  1/31  +2.2  41.67%  1347.57  _  
  
  
4.6   In vitro aggregation assays for the characterization of peptides 
abilities to inhibit the aggregation of PHF6* as full-length tau  
  
4.6.1   The potential of the selected L-enantiomer peptides to inhibit the 
aggregation of PHF6*  
  
To investigate the potential of the synthesized peptides MMP1, MMP2, MMP3, MMP4, 
MMP5 and MMP6 to inhibit the fibrillization of D-enantiomeric PHF6*, thioflavin 
fluorescence assays were performed. The ability of MM3, obtained in both selections, 
to inhibit the aggregation of D-PHF6* was also tested.  PHF6* fibril formation was 
detected in the presence and absence of tenfold more molar concentration of each 
peptide. The relative fluorescence value of the positive control (only PHF6*) after 30 
hours (saturation level) was set to 100%. As can be seen in Figure 23, peptides MMP2 
and MMP6 were the most potent PHF6* aggregation inhibitors; furthermore, MMP1 
and MMP4 reduced the fibril formation of PHF6*. In contrast, MMP5 did not inhibit 




which was previously confirmed by THT assay as full-length tau aggregation inhibitor, 
also acted as a potent PHF6* aggregation inhibitor (Figure 23).  
 
Figure 23: The ability of the selected peptides MMP1, MMP2, MMP3, MMP4, MMP5, MMP6 
and MM3 to reduce or inhibit D-PHF6* fibrils formation. ThT assays were performed using 
100 μM PHF6* in NaPi buffer with 10 μM ThT. The peptides were added in concentration of 
1000 µM to PHF6* solution respectively. NaPi and 10 μM ThT without addition of PHF6* was 
used as a negative control. Solutions were pipetted into a black 96-well half area µclear 
flatbottom plate and incubated at RT for 42 hours. The relative fluorescence intensity was 
measured at excitation and emission maxima of 450 and 482 nm, respectively (mean +/- 
standard deviations of results, three replicates per run). The relative fluorescence for the 
positive control (only PHF6*) after reaching the saturation level (30 hours of incubation) was 
set at 100%.  
  
Peptides MMP2 and MMP6 were selected for further characterization to test their ability 
to inhibit the aggregation of full-length tau. Both MMP2 and MMP6 were synthesized 
as D-enantiomeric peptides and named as MMPD2 and MMPD6 respectively.  
  
4.6.2   The potential of the MMPD2 and MMPD6 to inhibit the aggregation of full-
length tau  
  
To test the ability of MMPD2 and MMPD6 to inhibit the fibrillization of full-length tau, 
similar thioflavin assays to those described above were carried out with full-length tau. 
Tau, heparin and MMPD2 or MMPD6 were incubated. As a control, MMD3, which was 





























control, tau was incubated with heparin and the relative fluorescence of the samples 
after reaching the saturation level were calculated in percent (Figure 24). Neither 
MMPD2 nor MMPD6 inhibited the aggregation of full-length tau. Indeed, MMPD6 even 
appeared to increase tau aggregation. MMD3, which was obtained in both the selection 
against full-length tau and the selection against D-PHF6* fibrils, showed again its ability 
to inhibit the aggregation of full-length tau.  
 
Figure 24: The ability of the selected peptides MMPD2, MMPD6 and MMD3 to reduce or 
inhibit tau fibril formation. 24 µM tau, 6 µM heparin and 10 µM ThT were incubated with and 
without the peptides in a molar ratio of 1:10 (tau:peptide), respectively. Samples were pipetted 
into each well of a black 96-well µclear flat-bottom plate and incubated at 37°C for 72h in 
photometer POLARstar Optima. The relative fluorescence intensity was read out at excitation 
and emission maxima of 450 and 482 nm, respectively (mean +/- standard deviations of 
results, three replicates per run). The relative fluorescence for the positive control (tau and 
heparin without peptides) after reaching the saturation level (36 hours of incubation) was set 
at 100%.  
  
The peptides that were selected against the PHF6* motif were not used for further 
investigation, with the exception of peptide MMD3. Thus, further investigations on 
MMD3 and MMD3rev were performed.  
  
4.6.3   The potential of the MMD2, MMD2rev, MMD3 and MMD3rev to inhibit the 















Given the observation that MM3 acted as a tau aggregation inhibitor as well as a PHF6* 
aggregation inhibitor, we hypothesized that MM3 is a specific inhibitor for PHF6* 
fibrillization. To test this possibility, the potential of MMD2, MMD2rev, MMD3 and 
MMD3rev to inhibit the aggregation of PHF6* segment as well as the aggregation of 
PHF6 segment were tested using thioflavin assays.  
  
To test whether MMD3, MMD3rev, MMD2 and MMD2rev reduce PHF6* fibril formation, 
1000 µM from the respective peptides were incubated with 100 µM PHF6* at RT. As    
a positive control, PHF6* was incubated alone. The relative fluorescence of THT was 
monitored over 30 h. As expected, MMD3 and MMD3rev, which were selected against 
PHF6* fibrils, inhibited the formation of PHF6* fibrils, while MMD2 and MMD2rev did 
not inhibit the fibrillization of PHF6* (Figure 25 A).  
  
To evaluate the ability of MMD3, MMD3rev, MMD2 and MMD2rev to inhibit the 
aggregation of PHF6, 500 µM from the respective peptides were incubated with 50 µM 
PHF6 at RT. As a positive control, PHF6 was incubated alone. The relative 
fluorescence of THT was monitored over 30 h. As shown in Figure 25 B, PHF6* 
inhibitors MMD3 and MMD3rev did not affect the formation of PHF6 fibrils. In addition, 
MMD2 and MMD2rev, which were selected against full-length tau, did inhibit the 
fibrillization of PHF6.  













Figure 25: MMD3 and MMD3rev inhibit the aggregation of PHF6* but not of PHF6, while 
MMD2 and MMD2rev neither inhibit the aggregation of PHF6* nor of PHF6. (A) PHF6* 
fibrillization was performed by incubating 100 μM PHF6* in NaPi buffer with 10 μM ThT at room 
temperature (black line). NaPi and 10 μM ThT without addition of PHF6* was used as control 
(brown line). Peptides MMD2, MMD2rev, MMD3 or MMD3rev were added in concentrations of 
1000 μM to 100 μM PHF6* samples (light blue line, blue line, light green line and green line 
respectively). Fluorescence was measured at 450/482 nm in relative units (mean +/- standard 
deviations of results, three replicates per run). Low ThT signals were observed in the samples 
treated with D-peptides MMD3 and MMD3rev, which indicates an inhibition of PHF6* 
aggregation. Samples treated with MMD2, MMD2rev do not exhibited a reduction in ThT 
signals, which indicates no inhibitory effect on PHF6* fibril formation (B) PHF6 fibrillizes 
spontaneously via incubation at room temperature. The assay was performed using 50 μM 
PHF6 in NaPi buffer with 10 μM ThT (black line). 10 μM ThT in NaPi without addition of PHF6 
was used as negative control (brown line). Peptides MMD2, MMD2rev, MMD3 or MMD3rev 
were added in concentrations of 500 μM to 50 μM PHF6 samples (light blue line, blue line, 
light green line and green line respectively).  Fluorescence was measured at 450/482 nm in 
relative units (mean +/- standard deviations of results, three replicates per run). Samples 
treated with all D-peptides do not exhibited a reduction in ThT signals, which indicates no 
inhibition of PHF6 fibril formation.  
  
4.7   Demonstrating the binding properties of the MMD2 and MMD3 
to PHF6* fibrils, as well as to PHF6 fibrils using ELISA  
  
To evaluate the binding properties of MMD2 and MMD3 to both PHF6 fibrils and PHF6* 
fibrils, ELISA was performed with a FAM-labeled version of the peptides. The plate was 
coated with 50 µg/ml PHF6 fibrils as well as PHF6* fibrils and as a negative control, 




concentrations and the bound peptides were detected with anti-FAM antibodies. After 
adding the substrate, the absorption at 450 nm, representing the binding affinities, was 
measured.   
As shown in Figure 26, both MMD2 and MMD3 bound to both PHF6 fibrils and PHF6* 
fibrils. Unexpectedly, MMD2, which did not inhibit the aggregation of tau, showed 
significantly higher binding signal to PHF6 fibrils. In contrast, MMD3, which inhibited 
both the aggregation of full-length tau as well as PHF6*, showed higher binding signal 
to PHF6 fibrils than PHF6* fibrils.  
  
 
Figure 26: The binding properties of peptides MMD2 and MMD3 to PHF6 fibrils and 
PHF6* fibrils were tested using ELISA. To enable the use of this method, a FAM-labeled 
versions of the peptides were synthesized. The plate was coated with PHF6 fibrils and PHF6* 
fibrils in 50 μg/mL concentration. As a negative control, coating buffer only was incubated in 
the wells. After blocking with 1% BSA in PBS, the peptides MMD2-FAM and MMD3-FAM were 
added in increasing concentrations (10 µg/ml, 20 µg/ml and 50 µg/ml), a horseradish 
peroxidase-conjugated sheep anti-FITC secondary antibody was used to detect the bound 
peptide. Subsequently, the TMB substrate solution was transferred to the relevant wells. 
Finally, the enzymatic reaction was stopped with 20% H2SO4 and the plate was read at 450 
nm. The absorption values were presented after subtraction of the negative controls. The mean 
of three absorption values (at 450 nm) is shown, as well as the standard deviation.   
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4.8   Thioflavin assays to test whether the PHF6*- based inhibitors 
are more potent in inhibiting the aggregation of full-length tau than 
PHF6-based inhibitors  
  
To test whether inhibitors based on the structure of the PHF6* segment are more potent 
in inhibiting tau fibrillization than inhibitors based on the structure of the PHF6, we 
compared the tau aggregation inhibiting effects of PHF6* inhibitors MMD3 and 
MMD3rev with another peptide, designated APT, which was selected against PHF6 
fibrils earlier by our group (Dammers et al, 2016). We further tested the performance 
of two peptides previously described in the literature, designated “Sievers” and 
“W.MINK”, which bind to PHF6 and PHF6*, respectively.   
  
Thioflavin assays were performed by incubating full length tau with heparin at 37 °C, 
the peptides were added at increasing concentrations (molar ratio 1:1, 1:5 and 1:10). 
The relative fluorescence of the positive control (tau with heparin) after reaching the 
saturation level was set at 100%. As shown in Figure 27, PHF6-based inhibitors 
(“Sievers” and APT) were able to hinder the aggregation of full-length tau with a similar 
potency to PHF6* based inhibitors (MMD3 and MMD3rev) at molar ratios of 1:5 and 
1:10. At molar ratio 1:1, APT was the most effective peptide in blocking the seeding of 
tau protein. Conversely, W.MINK, a PHF6* binder, was in our hands less effective than 
the other peptides in reducing the aggregation of tau. In this assay, W.MINK even 






Figure 27: ThT assays to test whether the PHF6* based-inhibitors are more potent in 
inhibiting the aggregation of full-length tau than PHF6 based-inhibitors. The performance 
of the peptides selected in this project (MMD3 and MM3rev) were compared to the 
performance of already published peptides: APT, selected by our group against PHF6 fibrils 
(Dammers et al., 2016), TLKIVW (Sievers et al., 2011) and W.MINK (Seidler et al., 2018), 
which target PHF6 and PHF6*, respectively. 24 µM tau and 6 µM heparin were incubated at 
37°C with and without the peptides at a molar ratio of 1:1, 1:5 and 1:10 (tau:peptide), 
respectively. After adding of ThT, fluorescence was measured at 450/482 nm in relative units 
(mean +/- standard deviations of results, three replicates per run). The relative fluorescence 
for the tau and heparin control without peptides after reaching the saturation level (36 hours 
incubation) was set at 100%. Numbers over the columns of the chart represent the value of 































5   Discussion  
  
AD is characterized by the accumulation of Aß plaques and tau tangles in the brain. 
Tau aggregation is associated with more than 20 neurodegenerative disease, the most 
common of which is Alzheimer’s disease (Terry et al., 1964; Kidd, 1963; Terry 1963; 
1998; Ballatore et al., 2007). Since Aβ and tau were identified, AD therapeutic research 
has predominately focused on Aβ. However, tau-targeting strategies have gained more 
attention in recent years, in part because Aβ-targeting treatments have largely proven 
unsuccessful in clinical trials, in addition, studies have revealed that tau pathology 
(neurofibrillary tangles) correlates more closely with the severity of AD than Aß 
pathology (Arriagada et al., 1992).   
Initially, one of the potential anti-tau therapy strategies was based on the inhibition of 
tau aggregation. Compounds that inhibit tau fibrillization may lead to prevent the spread 
of tau pathology (Congdon and Sigurdsson, 2018). Methylene blue is an effective tau 
aggregation inhibitor. This agent reduces tau pathology and improves cognitive 
phenotypes in transgenic mouse models of tauopathy (Panza et al., 2016). In addition, 
the methylene blue derivative (LMTX) reached the clinical trials phase III with AD 
patients and showed improvement in patients with mild or moderate AD who took 
LMTX alone without any other AD treatments. However, an additional phase III clinical 
trial was recently terminated to assess the effectiveness and the long-term safety of 
the drug (https://clinicaltrials.gov/show/NCT01689233 (2018)).  
D-enantiomeric peptide-based drugs have become reasonable alternatives to chemical 
pharmaceuticals, and gained an extraordinary degree of scientific interest in their 
potential usage. D-enatiomeric peptides are highly resistant to proteases. In addition, 
they can be absorbed systemically after oral administration. Furthermore, Dpeptide 
immunogenicity has been demonstrated to be reduced in comparison to Lpeptides 
(Milton et al., 1992; Pappenheimer et al., 1994; Chalifour et al., 2003; Sadowski et al., 
2004; Pujals et al., 2007). A variety of small peptides that target tau pathology and 
reduce its toxic effects have already been described and a fraction of them proved to 
be effective in AD animal models. Davunetide (DAP) is an eight amino acid peptide 
that targets tau pathology and promotes MT assembly. It has been shown to decrease 




considered as an inhibitor of tau fibrillization (Shiryaev et al., 2009; Matsuoka et al., 
2008).  
The formation of tau aggregates is triggered by two hexapeptide sequences within tau: 
275-VQIINK-280 (PHF6*) und 306-VQIVYK-311 (PHF6). Both fragments are 
interesting targets for the development of tau aggregation inhibiting compounds, and 
some peptides were already described. The D-enantiomeric peptide, TLKIVW, was 
rationally designed by the Eisenberg group on PHF6 fibrils as templates and was 
shown to prevent the aggregation of PHF6, and of the truncated tau constructs (K12 
and K19) (Sievers et al., 2011). In addition, our group selected D-enantiomeric peptides 
APT, KNT, APS, TD28 and TD28rev, which interact with PHF6 fibrils in a manner 
analogous to TLKIVW and inhibit the formation of PHF6 fibrils as well as fulllength tau 
fibrils (Dammers et al., 2016). Recently, in 2018, the Eisenberg group developed a new 
peptide, designated W.MINK, using the PHF6* fibrils as templates for a structure-based 
inhibitor design. W.MINK inhibits the aggregation of full-length tau in HEK293 
biosensor cells (Seidler et al., 2018).  
  
In this thesis, D-enantiomeric peptides were selected using phage display and mirror 
image phage display in order to inhibit the fibril formation of tau. For the phage display 
selection, tau monomer was used as a target in order to obtain peptides that inhibit the 
aggregation process at a very early stage, since tau pathological aggregation begins 
from tau monomers. For the mirror image phage display selection, the selection was 
performed against D-PHF6* fibrils, as in 2018 the Eisenberg group hypothesized that 
PHF6* is a more powerful driver for tau aggregation and that inhibitors of PHF6* 
aggregation are highly effective at preventing the aggregation of full-length tau (Seidler 
et al., 2018).  
  
5.1   Expression and purification of recombinant tau protein  
  
Efficient production of recombinant tau protein is required for the in vitro screening of 
tau aggregation inhibitors. In vitro tau fibrillization assays required significant quantities 
of tau and the presence of anionic inducer such as heparin.  
  
Full-length tau protein with 441 amino acids (tau441 or tau 2N4R) was expressed and 




KrishnaKumar et al., 2017, with minor modifications in each protocol. For purification, 
the heat stability of tau is an effective tool to remove host specific proteins. Therefore, 
cell lysate containing tau protein can be boiled and tau remains in the supernatant, 
maintaining its physiological function. The majority of other proteins, including 
proteases, become insoluble and precipitate under these conditions (Cleveland et al., 
1977).  
  
As described by Margittai and coworkers, tau-containing lysate was boiled and then 
purified using various purification methods, including ammonium sulfate precipitation, 
cation exchange chromatography and anion exchange chromatography. The overall 
yield of tau was about 3 mg from 1L culture. Most of tau protein expressed according 
to this method was used in the phage display selection against tau monomer.   
  
In 2017, KrishnaKumar and his colleagues demonstrated a simplified method to obtain 
tau protein from E.coli with one-step purification. After boiling of the lysate, tau was 
purified using cation exchange chromatography. Here, some lower molecular 
additional bands were observed on the gel after performing the SDS-PAGE (Figure 
11). Using Western blot analysis with the tau specific antibody anti-TAU5, we observed 
that all additional bands reacted with the tau specific antibody, indicating that all 
fragments are degradation products of tau and belong to the recombinant protein tau 
(Figure 12). All protein expressed according to this protocol was used in the 
subsequent thioflavin T aggregation assays. Thioflavin T aggregation assays with tau 
protein obtained from both protocols were performed under the same conditions, we 
observed that the kinetic courses of aggregation were the same, which indicated that 
these small amounts of degradation products did not alter the aggregation kinetics of 
tau.  However, the method reported by KrishnaKumar et al. offers a fast and low cost 
method in comparison to currently existing methods. Our overall yield of tau from this 
protocol was about 3 mg from 1L culture, while the expressed yield achieved by 







5.2   Selection of full-length tau binding peptides using phage 
display  
  
To select peptides that bind to full-length tau protein and inhibit the pathological 
aggregation of tau, a phage display selection against tau monomers was performed.  
Tau monomer was used as a target, as studies suggest that targeting the early phase 
of the aggregation process is useful to reduce potential toxic oligomers and fibrils 
formation. In addition, small peptides that bind to the monomeric proteins could inhibit 
their aggregation and stabilize their functional native states (Pickhardt et al., 2015).  
Four panning rounds were carried out and enrichment ELISA was performed to 
evaluate the binding properties of the amplified phage pools of each panning round, 
which contain a population of phages, to tau monomer. High binding signals of the 
phage pools from rounds 1-4 to tau monomer were observed compared to the very low 
signal of the phage pools in the negative control wells (Figure. 13). As expected, during 
successive rounds of the selection process, enrichment of phages that bind to the 
target protein was observed with an increasing number of panning rounds. The 
maximum enrichment was obtained in the fourth panning round.  
In the literature, some phage display selections have been carried out with additional 
rounds of panning, such as the mirror image phage display selection described by 
Rudolph et al., 2016 against Aß. They performed six rounds of panning, while the mirror 
image phage display selection of Dammers et al. 2016 against PHF6 fibrils was 
performed with four panning rounds. However, we avoided the performing of more than 
four panning rounds as it could lead to an increase in the fast growing phages in the 
later rounds of panning, according to the recommendations of the manufacturer.   
The enrichment in phage pools can be estimated after rounds of selection by 
calculating the binding ratio. A binding ratio >2 usually indicates a phage pool with 
specific binding phages. In contrast, a low ratio <2 may indicate a failure in the 
biopanning procedure. Furthermore, a ratio <2 with high negative control absorbance 
may indicate a presence of non-specific clones (such as plastic binders) in phage pool 
(Miersch et al., 2015).  
In our selection, the binding ratio for all panning rounds was >2 (Table 8). An 




properties of single clones from the third and fourth panning rounds were evaluated 
using single phage ELISA. Usually, individual clones are isolated from the last rounds 
of panning (usually the enriched rounds of panning) (Zadeh et al., 2019). In single 
phage ELISA, the amplified pool of phages after the panning round was plated on 
IPTG/Xgal plates and single clones were picked and prepared to obtain a solution 
conations only single phage clone. This method is useful to screen individual single 
phages from a population of phages. The binding properties of approximately 96 phage 
clones to full-length tau monomer were estimated using single phage ELISA. The 
single phage ELISA revealed several phages with a high signal in the wells coated with 
tau monomer, indicating the likely presence of binding phages to tau monomer. 
 
The DNA of approximately 45 promising phage clones was extracted and sent for 
sequencing. Of these, 28 sequences could be identified after DNA sequencing. As 
some peptide sequences were identified more than once, the 28 identified sequences 
actually indicated 22 different peptides. These 22 sequences were then screened using 
screening web tools to exclude possible target-unrelated peptides.   
In some phage display studies, the frequent occurrence of a peptide indicates that it is 
more likely to be a target-specific binding peptide (Agrawal et al., 2016). In the study 
by the Willbold group, Wiesehan et al. 2003, the most promising peptides D1 and D3, 
which were selected against D-Aß1-24 by mirror image phage display, were dominated 
in the selections. D1 was obtained in 20 of 39 selected peptides and D3 was obtained 
in 9 of 23 selected peptides. However, in the study of Rudolph et al., 2015 from the 
same group, after performing mirror image phage against D-Aß1-24 the DNA of 272 
single phage clones was sent for sequencing. While several sequences obtained 
repeatedly and two sequences were found in 39 and 28 clones, the most promising 
peptide in his study occurred only once (Rudolph, 2015). In our study, the most 
promising peptide MMD3 also occurred only once in both performed selections (the 
selection against tau monomer and the selection against D-PHF6*). Hence, it seems 
reasonable to assume that the frequent occurrence of a peptide does not necessarily 
indicate that it is more likely to be a target-specific binding peptide.  
After excluding possible target-unrelated peptides using SAROTUP, the remaining 
phages were further tested for their binding to tau monomers by single phage ELISA 




accurately compare the binding properties of different phage clones to the target tau. 
After amplifying each phage stock and titering the obtained phage solution, the same 
phage concentration from each individual phage solution was added to the tau-coated 
wells. Phages with relatively high absorption values comparing to the negative controls 
indicated a binding to the tau protein.  
Finally, 8 peptides (MM1, MM2, MM3, MM4, MM5, MM6, MM7 and MM8) were selected 
to be synthesized as L-enantiomeric peptides to test their ability to inhibit the fibril 
formation of full-length tau protein.  
     
The ability of the selected full-length tau binding peptides to inhibit the 
aggregation of full-length tau  
  
After performing thioflavin T aggregation assays, two L-enantiomeric peptides, MM2 
and MM3, showed their ability to inhibit the fibrillization of full-length tau (Figure 17). 
The D-enantiomeric form (MMD2, MMD3), as well as the D-enantiomeric-retro-inverso 
form (MMD2rev, MMD3rev), of both MM2 and MM3 were synthesized and tested for 
their ability to inhibit tau fibril formation. D-retro-inverso peptides are of particular 
interest. These have a reversed sequence of D-amino acids leads, and thus constitute 
molecules with almost the same structure and bioactivity as the original L-peptides, but 
with an increased resistance to proteolytic degradation (Chorev and Goodman, 1995; 
Fletcher et al., 1998).   
THT aggregation assays indicated that while MMD2 and MMD2rev did not inhibit the 
aggregation of full-length tau protein, MMD3 and MMD3rev prevented significantly the 
formation of tau fibrils (Figure 18).  
Other D-peptides were described in the literature and showed their ability to inhibit tau 
fibril formation. The D-peptides APT, KNT, LPS, TD28 and TD28rev which were 
developed against PHF6 fibrils by our group, inhibited the aggregation of full-length tau 
effectively when using the molar ratio (1:10) (tau:peptide) in THT assays (Dammers et 
al., 2016). Another D-peptide, TLKIVW, developed by computer-aided, structure-based 
design against PHF6 fibrils by Eisenberg group, also showed its ability to inhibit the 
formation of tau fibrils. The inhibitory effect of Sievers’ peptide was also observed in a 




full-length tau, but against tau construct K12 (tau sequence 244-294) (Sievers et al., 
2011).   
After testing the inhibitory effect of MMD2 and MMD3, the peptides were further 
characterized. The binding of MMD2 and MMD3 to full-length tau was demonstrated 
using ELISA (Figure 19). Both MMD2 and MMD3 bound to tau monomers and fibrils, 
with a minimal preference for tau monomers. However, there was no significant 
difference between the absorption values of wells containing tau monomers and wells 
containing tau fibrils. In the study of Dammers et al., the binding of the selected 
peptides in her study to tau monomers and tau fibrils were also demonstrated using 
ELISA. These peptides also bound with minimal preference to tau monomers. In both, 
Dammers study and this study, the preference of the selected peptides to tau 
monomers was not significant; the light preference to tau monomers may be due to the 
fact that the binding sites of tau monomers are more accessible than tau fibrils.  
  
The binding of MMD3 to tau monomers and tau fibrils was expected as MMD3 was 
obtained in the selection against tau monomers, and its binding site on tau monomers 
also available within tau fibrils. Also, MMD3 showed an effective inhibitory effect on tau 
fibril formation. Unexpectedly, MMD2 exhibited a stronger binding to both tau 
monomers and tau fibrils, while it did not prevent the formation of tau fibrils. It seems 
likely that the binding site for MMD2 on the tau does not involve inhibition of tau 
aggregation.  
  
5.3   Selection of D-peptide against D-PHF6* fibrils using mirror 
image phage display  
  
The two six-residue segments within tau, VQIVYK (PHF6) and VQIINK (PHF6*), 
promote the formation of amyloid aggregates of tau. PHF6 has been proposed to play 
a dominant role over PHF6* by initiating and stabilizing the tau fibrils (von Bergen et 
al., 2000; von Bergen et al., 2001; Barghorn et al., 2014). By targeting PHF6 fibrils, our 
group developed D-peptides that inhibit fibril formation of full-length tau in vitro 
(Dammers et al., 2016).  
  
In 2018, the studies of Seidler and his coworkers suggested that the PHF6* segment 




fulllength tau fibrils formation. Therefore, we proposed that a comparative study to the 
previous research may be of interest and developing D-peptides that inhibit the 
aggregation of PHF6* could be a highly effective method for blocking the aggregation 
of full-length tau.  
  
A mirror image phage display selection was performed using D-PHF6* fibrils. As short 
synthetic peptides such as PHF6* are difficult to adsorb on a plate, we prepared fibrils 
of D-enantiomeric PHF6* to be immobilized on the plastic surface of multi-well plates. 
The D-PHF6* fibrils were prepared by incubating D-PHF6* peptide, without adding of 
heparin, in RT for 30 h. Four panning rounds were performed and enrichment ELISA 
was carried out to estimate the success of the selection (Figure 21).  
  
In this selection, no enrichment in phage pools was observed in rounds 3–4. Usually, 
an enrichment in the phages pool against the target protein is expected with an 
increasing number of panning rounds. However, the binding ratio for all panning rounds 
eluates was >2, which indicates the likely presence of specific binding phages (Table 
11). The binding properties of single clones from the third and fourth panning rounds 
were evaluated by single phage ELISA. The eluates of the third and fourth panning 
rounds were used despite their lower binding ratio in comparison with the elutes of the 
first and second rounds. This was due to the common experience in phage display that 
later rounds are more likely to contain the promising phages. This can be explained by 
the fact that with increasing rounds of panning, the amplified elutes of the later rounds 
are more enriched with population of phages more likely to be specific binding phages. 
About 60 phage clones were screened for their binding to PHF6* fibrils by single phage 
ELISA. The outcome of the single phage ELISA revealed several clones with a high 
signal in the wells coated with PHF6* fibrils. Phage clones which exhibited a high signal 
to PHF6* fibrils are more likely to be target binding phages.  
  
The DNA of about 40 promising phage clones was extracted and sent for sequencing. 
31 sequences could be identified after DNA sequencing and as some peptide 
sequences were identified more than once, these 31 identified sequences indicated 29 
different peptides. These 29 sequences were then screened using screening web tools 
to exclude possible target-unrelated peptides. Interestingly, peptide MM3, which was 




inhibitor, was also among the selection against PHF6* fibrils. Finally, 6 peptides 
(MMP1, MMP2, MMP3, MMP4, MMP5 and MMP6) were selected to be synthesized as 
L-enantiomeric peptides to test their ability to inhibit the aggregation of D-PHF6*. 
  
The inhibitory effects of the selected PHF6*-based inhibitor peptides   
  
Usually, the peptides obtained after mirror image phage display are synthesized 
directly as D-peptides and tested against the L-enantiomeric form of the target. 
However, due to the high cost of synthesizing six D-enantiomeric peptides, we decided 
to order them first in the L-enantiomeric form and test them against already available 
D-PHF6* using THT. Two promising peptides (MMP2 and MMP6) were then 
synthesized in the D-enantiomeric form (named MMPD2 and MMPD6) and tested 
against full-length tau. However, Neither MMPD2 nor MMPD6 prevented the fibril 
formation of full-length tau.  
As previously mentioned, MM3, which was selected against tau monomer, was also 
found in the selection against PHF6* fibrils. Therefore, it was of interest to test the 
ability of MMD3 and MMD3rev to inhibit the aggregation of PHF6*. After performing 
THT aggregation assays with PHF6*, both MMD3 and MMD3rev showed their ability 
to inhibit the fibril formation of PHF6*. In addition, we tested the ability of MMD3 and 
MMD3rev to inhibit the aggregation of PHF6. However, neither peptide was able to 
inhibit the PHF6 aggregation. These results were to be expected as MM3 was selected 
against PHF6* rather than PHF6.   
In addition, the ability of MMD2 and MMD2rev, which were obtained in the selection 
against tau monomer, to inhibit the aggregation of PHF6* and PHF6 was tested using 
a THT assay. Neither of these peptides exhibited any inhibitory effect on PHF6* or 
PHF6 fibril formation (Figure 25). This was also expected as MM2 was found only in 
the selection against full-length tau and not against PHF6*. It seems likely that the 
binding site for MM2 on the tau is not located on PHF6 or on PHF6*.  
Next, the binding behavior of MMD3 and MMD2 toward PHF6* and PHF6 fibrils was 
tested using ELISA. Both MMD2 and MMD3 exhibited high signals to PHF6* fibrils as 
well as to PHF6 fibrils, which demonstrated the binding of the selected peptide toward 
PHF6* and PHF6 fibrils. However, MMD2 exhibited stronger signals than MMD3 




both PHF6* and PHF6 fibrils (Figure 26). However, these findings could be considered 
somewhat controversial. While it was expected that MMD3 exhibited its binding to 
PHF6* fibrils, it was not expected that MMD3 exhibited any binding ability to PHF6 
fibrils, as MMD3 was selected against PHF6* and not against PHF6. In addition, the 
strong binding of MMD2 toward PHF6* as well as PHF6 fibrils was somewhat 
unexpected as MMD2 was not selected against either PHF6 or PHF6*. Taking in 
consideration our findings that MMD2 was ineffective at inhibiting the aggregation of 
full-length tau, PHF6* and PHF6, despite its strong binding to each, it seems likely that 
MMD2 is a non-specific binding peptide resulting from a non-target specific phage.  
  
Regarding MMD3, unexpectedly the peptide showed a stronger binding to PHF6 fibrils 
than PHF6* fibrils. This could be explained by the fact that the two segments PHF6 
(VQIVYK) and PHF6* (VQIINK) have a very similar sequence with only two different 
amino acids. However, despite this similarity MMD3 did not exhibit any inhibiting effect 
on PHF6 fibrils formation while acted as an effective inhibitor for PHF6* aggregation 
(Table 13).  
  
Table 13: Promising D-enantiomeric peptides selected during this project, and their 
potential to inhibit the full-length tau fibrillization, PHF6* fibrillization and PHF6 fibrillization 
according to THT assays.  
Peptide 
name   







Inhibition of  
PHF6   
fibrillization  
MMD2  d-ltphkhhkhlha  Tau 
monomer  
+/-  -  -  
MMD2rev  d-ahlhkhhkhptl  Tau 
monomer  
+/-  -  -  




+    
+  -  
  





+  +  -  




Concerning the influence of charge and hydrophobicity of the D-peptides on the 
interaction with target protein, the group of Willbold addressed also this question in a 
recent publication by Ziehm et al. in 2018. They presented a detailed biophysical 
characterization of the interactions between the D-enantiomeric peptide D3 and 
optimized D-peptides ANK3 and ANK6 with their molecular target, the Aß monomer. 
D3 was selected previously by the same group using mirror image phage display 
against Aß. D3 showed its ability to inhibit the aggregation of Aß in vitro as well as in 
vivo. In order to increase drug efficacy, Ziehm et al. optimized the lead peptide, D3, by 
peptide microarrays resulting in D-peptides (named as ANK3 and ANK6) with 
increased hydrophobicity. The hydrophobicity of ANK3 and ANK6 was increased by 
exchanging some amino acids in D3 to hydrophobic amino acid residues. It was 
revealed that ANK3 was the most promising peptide, and its hydrophobic interactions 
significantly contribute to the driving force for binding, resulting in a more robust 
complex formation. They concluded that increased hydrophobicity resulted in an 
increased affinity binding mode.  Later, ANK3 will be further studies in vivo to 
investigate whether increased hydrophobicity indeed leads to an optimized drug for the 
treatment of AD (Ziehm et al., 2018).  
  
Comparing the physicochemical characteristics of MMD3 with MMD2, MMD3 was more 
hydrophobic than MMD2 (Table 14). Despite that MMD2 had a relatively high 
hydrophobicity, it was ineffective in inhibiting the aggregation of full-length tau. 
However, it is reported in the literature that the hydrophobic peptides are more likely to 
be polystyrene surface-binding peptides (Li et al., 2017).  
  
In the future, optimizing our peptides MMD2 and MMD3 by exchanging some amino 
acid could lead also to optimized peptides for the inhibition of tau aggregation.  
  
Table 14: Physicochemical characteristics of the D-peptides (MMD2 and MMD3) and the, 
the hydrophobicity was presented in two different scores; first, the hydrophobicity was 
calculated according to Kyte and Doolittle using the online tool ProtParam and expressed as 
GRAVY score. The higher the GRAVY score, the more hydrophobic the D-peptide. In addition, 
the Hydrophobicity was calculated in percentage using the online tool PEPTIDE2.0.  
  
Peptide   Sequence   Net charge   Hydrophobicity in  
(GRAVY score)  
Hydrophobicity in 
percentage  




MMD3  ywvsthraklpd  +1  -0.88  41%  
  
  
5.4   The effectiveness of PHF6* and PHF6 aggregation inhibitors in 
preventing the fibrils formation of full-length tau   
  
To date, it is not known which of the segments PHF6 and PHF6* is the more effective 
target for the therapy of Alzheimer ‘s disease. The study by Seidler and his colleagues 
suggested that PHF6* is likely an excellent target for the inhibitors of full-length tau 
fibril formation. Using THT, they compared the tau aggregation inhibition effect of the 
most promising PHF6*-inhibitor peptide developed in their study, named as W.MINK, 
with tau aggregation inhibition effect of a PHF6-inhibitor peptide, TLKIVW, developed 
by Sievers and his coworkers. According to data presented by Seidler et al., TLKIVW 
peptide was not able to significantly inhibit the aggregation of full-length tau in vitro 
(Sievers et al., 2011; Seidler et al., 2018). In the study of our group, Dammers et al. 
2016, the performance of the TLKIVW peptide described by Sievers et al. was also 
compared with results of the peptides selected in Dammers study. However, the 
TLKIVW peptide demonstrated a weak effect while all peptides selected in the study of 
Dammers and her colleagues clearly inhibited fibril formation of the tau protein.  
  
We performed preliminary experiments to investigate the hypothesis that PHF6* is the 
stronger driver of tau aggregation. THT assays were carried out to compare the tau 
aggregation inhibiting effects of the PHF6-based inhibitors, TLKIVW (Sievers et al., 
2011) and the peptide APT (Dammers et al., 2016), with the PHF6*-based inhibitors, 
MMD3, MMD3rev and W.MINK (Seidler et al., 2018) (Figure 27). We used an 
increasing concentration of each peptide in a molar ratio 1:1, 1:5 and 1:10. We 
observed that ThT fluorescence decreased with increasing concentration of the 
peptides, indicating a dose-dependent inhibition of full-length tau aggregation for all 
peptides.  
  
From our early preliminary data, it seems likely that PHF6* and PHF6 aggregation 
inhibitors are comparably effective in inhibiting the aggregation of full-length tau in THT 
test. Similar to the PHF6* aggregation inhibitors, MMD3 and MMD3rev, that inhibited 




and APT showed a similar ability to inhibit the formation of tau fibrils. While, MMD3 and 
MMD3rev inhibitory effect was very similar to TLKIVW, APT showed the best inhibitory 
effect in our THT assays especially in a ratio of 1:1. In our hands, W.MINK, a PHF6* 
aggregation inhibitor, was less effective than the other peptides in reducing the 
aggregation of tau. In addition, all tested peptides inhibit seeding by tau fibrils in a 
concentration-dependent fashion (Figure 27).  
  
It is notable to mention that all peptides tested above (TLKIVW, APT, MMD3, MMD3rev 
and W.MINK) were also tested in the Lab of Prof. Eckhard Madelkow in the German 
Center for Neurodegenerative Diseases (DZNE) for their ability to inhibit the 
aggregation of the tau construct TauRDΔK280 by ThS assay. Their results revealed 
that, except for the TLKIVW peptide, all other peptides (WINK, APT, MMD3 and 
MMD3rev) were effectively able to reduce the aggregation starting from ~1 µM 
concentrations. They used a concentration range of 1 nM to 200 µM from each peptide. 
Comparing with the concentrations used in our THT assays, we used higher 
concentrations of the peptides (24, 120 und 240 µM).  
  
Future research is required to further characterize all these peptides using different 
biochemical and biophysical methods to determine which of the both sequences, PHF6 
or PHF6*, is the more effective target for the development of tau aggregation inhibiting 
peptides.  



















6   Conclusion and outlook  
  
Alzheimer’s disease (AD) is characterized by extracellular deposition of Aβ peptide as 
amyloid plaques and intracellular accumulation of tau protein as neurofibrillary tangles. 
Development of compounds that inhibit tau protein aggregation is considered as a 
treatment strategy of AD, which can stop the disease progression.  
In this project, we developed inhibitors that prevent the pathological aggregation of tau. 
Therefore, we performed phage display and mirror phage display selections to obtain 
D-peptides that bind to tau and block its fibril formation. The first phage display 
selection was performed against the monomer form of full-length tau protein. The 
second selection was a mirror image phage display selection using the D-enantiomeric 
form of PHF6* fibrils as a target.  
The most interesting D-peptide MMD3 was found in both selections. MMD3 and its 
retro-inverso form MMD3rev were able to inhibit the aggregation of full-length tau as 
well as of PHF6* in THT aggregation assays. Furthermore, both MMD3 and MMD3rev 
bind to tau monomer, tau fibrils and PHF6* fibrils in ELISA experiments.  
In addition, we performed preliminary experiments to investigate the hypothesis that 
PHF6* is the more powerful driver of tau aggregation. Our early preliminary data may 
suggest that PHF6 and PHF6* aggregation inhibitors have a similar ability to inhibit the 
aggregation of full-length tau.   
Tau aggregation inhibiting effects of MMD3 and MMD3rev were also tested in the Lab 
of Prof. Eckhard Madelkow in the German Center for Neurodegenerative Diseases 
(DZNE) and they were able to able to prevent the aggregation in ThS assays at low 
concentrations (micromolar concentrations).  
Recently, MMD3 and MMD3rev were designed as Alexa 647-labeled peptides and 
tested for their ability to enter N2a cells in the Lab of Prof. Eckhard Madelkow. The 
treatment of tau expressing N2a cells with ALEXA 647 labeled D-peptides revealed 
that MMD3 and MMD3rev are able to penetrate the cell membrane and are stable over 
the whole incubation time (4 days). As a next step, the ability of the peptides to inhibit 




In addition, in silico modelling of the MMD3 and MMD3rev peptides complexes with 
PHF6* is also planned in order to gain a better understanding of the binding mode of 
the selected peptides to PHF6*. Furthermore, the binding kinetics of MMD3 and 
MMD3rev toward PHF6, PHF6* und Tau441 are proposed to be characterized using a 
BLItz™ system in the Lab of Prof. Eckhard Madelkow. The BLItz™ system provides a 
real time, label-free analysis of protein-protein interaction by employing Bio-Layer 
Interferometry (BLI) technology.   
The aggregation inhibitory mechanism of MMD3 and MMD3rev is also proposed to be 
investigated to determine whether the selected peptide prevents the aggregation (e.g. 
by blocking the forming of the fibrils), dissolves the aggregates or transforms e.g. the 
oligomers to amorphous rather than toxic species. Additionally, to evaluate the 
diagnostic and therapeutic potentials of MMD3 and MMD3rev for the diagnosis and 
treatment of AD, the blood-brain barrier transport of these D-peptides should be 
quantitatively evaluated. To do that, an in vitro blood-brain barrier cell culture model, 
previously established, that mimics the blood-brain barrier can be used (Liu et al., 
2010).  
In the Lab of Prof. Eckhard Madelkow, it is also planned to investigate the influence of 
MMD3 and MMD3rev on the inducible hippocampal brain sections of transgenic mice.  
Using inducible hippocampal brain slices from transgenic mice expressing 
proaggregant tau repeat domain carrying ΔK280 mutation (termed Tau(RD)ΔK), the 
ability of tau aggregation inhibitors to prevent tau aggregation and neurotoxicity could 
be studied (Messing et al., 2013).  
In the future, it is proposed to develop dimeric D-peptides which address PHF6 and/or 
PHF6* within one molecule. To do this, different peptides will be connected via linker 
molecules. It will be interesting to investigate the tau aggregation inhibitory effect of 
dimeric peptides against PHF6* (e.g. MMD3-MMD3) and dimeric peptides against 
PHF6 and PHF6* (e.g. APT-MMD3).  
Finally, as MMD3 and MMD3rev have shown to be successful inhibitors of tau 
aggregation in vitro, they will be further investigated for their therapeutic potential.  
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